

Independent Auditor's Report

To the Board of Directors
Niva Bupa Health Insurance Company Limited

Opinion

We have audited the financial statements of Niva Bupa Health Insurance Company Limited (the 'Company'), which comprise the statement of financial position as at March 31, 2025, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the years then ended, and notes to the financial statements, including a summary of material accounting policy information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2025 and its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India (SAs). Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in India, and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

As discussed in Note 33 to the Financial Statements, the Company has filed an application for forbearance of exceeding the Expenses of Management (EOM) over the allowable limit as per Expense of Management Regulations 2024 in respect of financial year 2024-25 with IRDAI, approval for which is yet to be received. Pending grant of forbearance by IRDAI, the consequential impacts, if any, of the above on the financial statements cannot be presently determined. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in the audit of the financial statements for the financial year ended March 31, 2025. These matters were addressed in the context of the audit of the financial statements as a whole, and in forming the auditor's opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the Auditor's responsibilities for the audit of the financial statements section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

Key audit matters	How our audit addressed the key audit matter
<u>Incurred Claims</u>	
- Incurred Claims are a significant expense for the Company - Liability for Incurred Claims are significant in magnitude and requires use of judgements and estimates based on actuarial assumptions - The determination of these liabilities is based on significant judgements relating to the data used, assumptions about future periods,	Using our internal specialist as part of our audit team, our audit procedures included the following: - We tested the design and operating effectiveness of controls around the input data used by the Company's Appointed Actuary - We have also tested the design and operating effectiveness of controls around the claims due and intimated claims recording process. Also assessed and tested the operating effectiveness of key controls relating to the claims handling process,



Key audit matters	How our audit addressed the key audit matter
and the use of actuarial estimation techniques - The risk adjustment for non-financial risk is the compensation that the Company requires for bearing the uncertainty about the amount and timing of the cash flows of the groups of insurance contracts. - With regards to the claims provision, the Company makes a provision for claims upon intimation, on receipt of documents, communication from co-insurer leader in cases of incoming co-insurance business etc. The estimates undergo a revision based on further information and the settlement amount could vary from the provision created	including controls over completeness and accuracy of the claim outstanding recorded - Determined whether the methodology and assumptions applied by the Company's Appointed Actuary are appropriate comparing it to our knowledge of industry standards and the Company's financial reporting requirements - We tested the reasonableness of the Company's Appointed Actuary's assumptions and methodology for calculation of - Liability for incurred claims and their roll forwards, - risk adjustment calculation for both premium and reserve risk - discounting applied on the actuarial cashflows - Tested on a sample basis, claims paid and provision created with payment proof, claim intimation documents and communication from co-insurer leader in cases of incoming co-insurance business, which are material to assess whether claims are appropriately paid, estimated and recorded - Performed analytical review procedures on the outstanding claims - Tested the arithmetical accuracy of computation of claims provision performed by the Company
Valuation of Investments	
The carrying values of Investments represents more than 80% of total assets as disclosed in the Financial Statements. - The valuation of all investments should be as per the investment policy framed by the Company in accordance with IFRS 9. - The classification and valuation of these investments is considered to be one of the matters of material significance in the Financial Statements due to the materiality of the total value of investments to the Financial Statements - The Company performs an impairment review of its investments periodically and recognizes impairment charge when the investments meet the trigger/s for impairment provision as per the criteria set out in the investment policy. Further, the assessment of impairment involves significant management judgement	To ensure that the valuation of investments and impairment provision considered in the Financial Statements is adequate, we have performed the following procedures: - Reviewed the manner in which the investments have been made by the Company - Tested the management oversight and controls over valuation of investments - Independently test-checked valuation of quoted and unquoted investments - Reviewed the basis of provisions accounted in respect of non-performing investments - Reviewed and assessed the adequacy with respect to management assessment of impairment charge on investments outstanding at the year end.



<u>Impairment on Re-insurance contract assets:</u>	
• "Re-insurance contract assets" is INR 39,59,247 ('000) as at the year end. • Due to the significance of the amount and judgement involved in assessing the recoverability of dues, this has been considered as key audit matter.	The audit procedures performed by us included the following: • Evaluation and testing of controls over the Re-insurance contract assets • Evaluating the adequacy of the process of reconciliation followed by the Company with respect to Re-insurance contract assets • Reviewed the details of co-insurance transactions uploaded on the ETASS portal by the Company and Other Insurance Companies and reconciled with the transactions accounted by the Company • Sending out direct confirmations of balances to select parties on a test check basis • We discussed with management and reviewed correspondences, where relevant, to identify disputes, if any, on any of the recoverable balances and reviewed the assessment of the management as to the requirement of provisioning, if any on the disputed dues.
<u>Information Technology systems</u>	
The Company is highly dependent on its information technology ("IT") systems for carrying out its operations and owing to the significant number of transactions that are processed on daily basis as part of its operations, which impacts key financial accounting and reporting items such as insurance revenue, insurance service expenses and investments among others. The controls implemented by the Company in its IT environment determine the integrity, accuracy, completeness and validity of the data that is processed by the applications and is ultimately used for financial reporting. These controls contribute to mitigating risk of potential misstatements caused by fraud or error. Accordingly, our audit was focused on key IT systems and controls due to the pervasive impact on the Financial Statements.	The audit procedures performed by us included the following: We involved our IT specialists to obtain an understanding of the entity's IT related control environment, perform risk-based testing and identification of IT applications, databases and operating systems that are relevant to our audit. Our area of focus, for the key IT systems relevant to financial reporting, included Access control, Program Change controls and Network Operations. In this regard - • we obtained an understanding of the entity's IT environment and key changes, if any, during the audit period that may be relevant to the audit • we tested the design effectiveness of the general IT controls over the key IT systems and applications that are critical to financial reporting • we tested the entity's controls to ensure segregation of duties, access rights controls • we conducted testing of manual and automated IT controls along with related interdependencies, where applicable and critical for financial reporting, to evaluate completeness and accuracy • we tested the security environment implemented by the entity to prevent, detect and respond to network security incidents • we tested compensating controls or performed alternate procedures to assess whether there were any unaddressed IT risks that would impact the controls or completeness and accuracy of data.



Responsibilities of Management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless management either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements for the financial year ended March 31, 2025 and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a



matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

The Company has prepared a separate set of financial statements under the provisions of the Companies Act, 2013 for the year ended March 31, 2025 in accordance with the Accounting Standards notified under the said Act, which have been jointly audited by us and T R Chaddha & Co. LLP. We have issued a separate auditor's report to the members of the Company dated May 7, 2025 on these financial statements.

The accompanying financial statements as at and for the year ended March 31, 2025 have been prepared, and this report thereon issued, solely for the management purpose. Accordingly, this report should not be used, referred to or distributed for any other purpose.

For **S.R. Batliboi & Co. LLP**

Chartered Accountants

ICAI Firm Registration Number: 301003E/E300005



per **Shrawan Jalan**

Partner

Membership Number: 102102

UDIN: 25102102BMOBFF8942

Place of Signature: Mumbai

Date: May 7, 2025



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Statement of Financial Position
As at March 31, 2025
(Rs. in 000's)

	Note	As at March 31, 2025	As at March 31, 2024
ASSETS			
Cash and cash equivalents	3	22,03,476	14,28,168
Investments	4	8,26,96,732	5,44,37,068
Re-insurance contract assets	5	39,59,247	57,74,716
Deferred tax assets	16 (b)	-	4,98,462
Property, plant and equipment	7	13,07,880	9,58,856
Intangible assets	8	3,09,627	3,43,409
Other assets	9	40,34,491	26,53,044
Total Assets		9,45,11,453	6,60,93,723
LIABILITIES AND EQUITY			
LIABILITIES			
Insurance contract liabilities	6	4,84,52,477	3,44,35,485
Borrowings	10	25,37,459	25,38,192
Deferred tax liabilities	16 (b)	5,04,098	-
Other liabilities	11	1,00,93,689	71,44,891
Total Liabilities		6,15,87,723	4,41,18,568
EQUITY			
Share capital	12	1,82,70,264	1,69,95,346
Other equity	12 (a)	1,46,53,466	49,79,809
Total Equity		3,29,23,730	2,19,75,155
Total Liabilities and Equity		9,45,11,453	6,60,93,723


The accompanying notes form an integral part of Financial Statements

As per our report of even date attached


For S.R. Batliboi & Co. LLP

Chartered Accountants

ICAI Firm Registration Number: 301003E/E300005

**For and on behalf of the Board of Directors of
Niva Bupa Health Insurance Company Limited**

Sridhar Srinivasan

Director

DIN: 07240718


Krishnan Ramachandran

CEO & Managing Director

DIN: 08719264


Shrawan Jalan

Partner

Membership No: 102102


Place: Mumbai

Date : May 07, 2025


Rajat Sharma

Company Secretary

Membership No: FCS7069


Vishwanath Mahendra

Chief Financial Officer

Place: New Delhi

Date : May 07, 2025

CIN - L66000DL2008PLC182918



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Statement of Profit or Loss
For the year ended March 31, 2025
(Rs. in 000's)


	Note	For the year ended March 31, 2025	For the year ended March 31, 2024
INCOME			
Insurance revenue	6	5,83,99,082	4,41,78,659
Insurance service expenses	6	(5,52,14,744)	(4,07,96,922)
Net expenses from reinsurance contracts	5	(6,14,645)	(4,83,287)
Insurance service result (A)		25,69,693	28,98,450
Investment income	15	47,58,840	30,81,437
Net impairment loss on financial assets		(1,327)	(209)
Total investment income (B)		47,57,513	30,81,228
Other income		1,45,776	36,928
Other operating expenses	13	(43,47,189)	(42,35,295)
Finance costs	14	(3,65,567)	(3,52,016)
Net other income and expense (C)		(45,66,980)	(45,50,383)
Profit before tax (D)=(A)+(B)+(C)		27,60,226	14,29,295
Income tax expense (E)	16 (a)	(7,31,191)	(3,65,749)
Profit for the year (F)=(D)+(E)		20,29,035	10,63,546

Statement of Other Comprehensive Income
For the year ended March 31, 2025

Profit for the year (F)=(D)+(E)		20,29,035	10,63,546
Other comprehensive income			
Items that will be reclassified to profit or loss subsequently			
Net fair value gains on financial assets		10,92,464	4,96,963
Income tax relating to items that will be reclassified	16 (a)	(2,74,951)	(1,25,075)
Total (G)		8,17,513	3,71,888
Items that will not be reclassified to profit or loss subsequently			
Remeasurement of defined benefit plans	20.1	(14,238)	(6,629)
Income tax relating to items that will not be reclassified	16 (a)	3,584	1,668
Total (H)		(10,654)	(4,961)
Total other comprehensive income for the year (I)=(G)+(H)		8,06,859	3,66,927
Total comprehensive income for the year (J)=(F)+(I)		28,35,894	14,30,473
Earnings per share	17		
- Basic earnings per share (Rs.) of Rs. 10/- each		1.16	0.67
- Diluted earnings per share (Rs.) of Rs. 10/- each		1.14	0.65

The accompanying notes form an integral part of Financial Statements

As per our report of even date attached




For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm Registration Number: 301003E/E300005




Shrawan Jalan
Partner
Membership No: 102102
Place: Mumbai
Date : May 07, 2025

 For and on behalf of the Board of Directors of
Niva Bupa Health Insurance Company Limited


Sridhar Srinivasan
Director
DIN: 07240718

Rajat Sharma
Company Secretary
Membership No: FCS7069



Krishnan Ramachandran
CEO & Managing Director
DIN: 08719264




Vishwanath Mahendra
Chief Financial Officer

Place: New Delhi
Date : May 07, 2025

CIN - L66000DL2008PLC182918

NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Statement of Cash Flows
For the year ended March 31, 2025
(Rs. in 000's)

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
A. Cash flows from the operating activities		
Premiums received from policyholders, including advance receipts	9,06,16,414	6,75,40,691
Payments to re-insurers, net of commission and claims	27,49,556	(29,64,946)
Payments from/to co-insurers, net of claims	(64,719)	(7,241)
Payment of claims	(3,61,35,533)	(2,61,54,564)
Payment of commission and brokerage	(1,51,72,951)	(1,12,91,329)
Payment of other operating expenses	(1,84,80,739)	(1,39,29,651)
Deposits, advances and staff loans, net	(1,36,267)	(46,812)
Goods and services tax paid, net	(67,23,252)	(48,71,257)
Other receipts		
- Provision against outstanding premium written back	6,452	10,521
- Provision against non performing investment written back	91,536	13,574
Net cash flows from operating activities	1,67,50,497	82,98,986
B. Cash flows from investing activities		
Purchases of property, plant and equipment	(3,12,624)	(58,628)
Purchases of intangible assets	(1,01,556)	(2,70,898)
Proceeds from sale of property, plant and equipment	594	1,190
Proceeds from sale of intangible assets	5,039	-
Purchase of investments	(5,99,27,951)	(4,76,97,359)
Sales of investments	3,30,89,147	2,69,67,018
Interests and Dividends received	37,72,879	22,42,816
Expenses related to investments	(1,531)	(1,167)
Net cash flows from investing activities	(2,34,76,003)	(1,88,17,028)
C. Cash flows from financing activities		
Proceeds from issue of share capital, net of share issue expenses	79,77,424	1,13,68,941
Interest paid	(2,67,500)	(2,67,500)
Payment of lease liabilities	(2,09,110)	(1,73,828)
Net cash flow from financing activities	75,00,814	1,09,27,613
D. Net increase in cash and cash equivalents	7,75,308	4,09,571
Cash and cash equivalents at the beginning of the year	14,28,168	10,18,597
Cash and cash equivalents at the end of the year	22,03,476	14,28,168
Net increase in cash and cash equivalents	7,75,308	4,09,571
Reconciliation of cash and cash equivalents with the balance sheet at the end of the year		
Cash and bank balances (refer Note 3)	22,03,476	14,28,168
Cash and cash equivalents at the end of the year	22,03,476	14,28,168

As per our report of even date attached
**For and on behalf of the Board of Directors of
Niva Bupa Health Insurance Company Limited**
For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm Registration Number: 301003E/E300005

Shrawan Jalan
Partner
Membership No: 102102
Place: Mumbai
Date : May 07, 2025
Sridhar Srinivasan
Director
DIN: 07240718

Rajat Sharma
Company Secretary
Membership No: FCS7069

Krishnan Ramachandran
CEO & Managing Director
DIN: 08719264

Vishwanath Mahendra
Chief Financial Officer
Place: New Delhi
Date : May 07, 2025
CIN - L66000DL2008PLC182918


NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Statement of Changes in Equity

For the year ended March 31, 2025

(Rs. in 000's)

Particulars	Share Capital		Other Equity				Fair value reserve	Total
	Issued share capital	Share based payment reserve	Share application money pending for allotment	Securities premium	Retained earnings			
As at April 01, 2024	1,69,95,346	2,33,803	1,915	1,29,10,127	(80,64,364)	(1,01,672)		2,19,75,155
Profit for the year ended March 31, 2025	-	-	-	-	20,29,035	-		20,29,035
Shares issued during the year	12,74,918	-	-	69,78,464	-	-		82,53,382
Transaction cost on issue of share capital	-	-	-	(2,99,243)	-	-		(2,99,243)
Employee stock compensation expense	-	1,35,257	-	-	-	-		1,35,257
Addition during the year	-	-	23,285	-	-	-		23,285
Other comprehensive Income-Defined benefit plan	-	-	-	-	(10,654)	-		(10,654)
Other comprehensive Income-Net fair value gains on financial assets	-	-	-	-	-	8,17,513		8,17,513
Transfer of ESOP Reserve on account of allotted options	-	(1,04,745)	-	1,04,745	-	-		-
Transfer of ESOP Reserve on account of lapsed options	-	(4,598)	-	-	4,598	-		-
As at March 31, 2025	1,82,70,264	2,59,717	25,200	1,96,94,093	(60,41,385)	7,15,841		3,29,23,730
As at April 01, 2023	1,51,06,779	2,11,087	-	33,71,223	(91,26,893)	(4,73,560)		90,88,636
Profit for the year ended March 31, 2024	-	-	-	-	10,63,546	-		10,63,546
Shares issued during the year	18,88,567	-	-	94,78,459	-	-		1,13,67,026
Employee stock compensation expense	-	87,105	-	-	-	-		87,105
Addition during the year	-	-	1,915	-	-	-		1,915
Other comprehensive Income-Defined benefit plan	-	-	-	-	(4,961)	-		(4,961)
Other comprehensive Income-Net fair value gains on financial assets	-	-	-	-	-	3,71,888		3,71,888
Transfer of ESOP Reserve on account of allotted options	-	(60,445)	-	60,445	-	-		-
Transfer of ESOP Reserve on account of lapsed options	-	(3,944)	-	-	3,944	-		-
As at March 31, 2024	1,69,95,346	2,33,803	1,915	1,29,10,127	(80,64,364)	(1,01,672)		2,19,75,155

Refer Note No. 12(a) for nature of other equity

As per our report of even date attached

For and on behalf of the Board of Directors of
Niva Bupa Health Insurance Company Limited

For S.R. Batliboi & Co. LLP

Chartered Accountants

(CA) Firm Registration Number: 301003E/ES000005

Sridhar Srinivasan

Director

DIN: 07240718

Krishnan Ramachandran

CEO & Managing Director

DIN: 08719264

Shrawan Jalan

Partner

Membership No: 102102

Place: Mumbai

Date: May 07, 2025

Rajesh Sharma

Company Secretary

Membership No: FCS7069

Place: New Delhi

Date: May 07, 2025

Vishwanath Mahendra

Chief Financial Officer



CIN - 16600070700891 C187918

1. CORPORATE INFORMATION

Niva Bupa Health Insurance Company Limited ("The Company") was incorporated in India on September 05, 2008 and received the Certificate of Commencement of Business on December 23, 2008.

As on balance sheet date, Bupa Singapore Holdings Pte Ltd is the holding Company with 56% shareholding.

The Company underwrites primarily Health Insurance business which includes Personal accident, Critical illness and Travel.

The Company obtained regulatory approval to undertake Health Insurance business on February 15, 2010 from Insurance Regulatory and Development Authority of India (IRDAI) under section 3(2A) of the Insurance Act, 1938. The Company had started selling policies in March 2010.

2. SUMMARY OF MATERIAL ACCOUNTING POLICIES

2.1 STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), including any applicable interpretations by the IFRS Interpretations Committee.

2.2 BASIS OF PREPARATION

The financial statements have been prepared under the historical cost convention, except for certain financial instruments that are measured at fair value at the end of each reporting period. The financial statements have been prepared on going concern basis, which assumes that the Company will continue in operational existence for the foreseeable future. In making this assessment, management has considered a wide range of factors relating to present and future conditions, including current profitability, expected future profitability, cash flows and access to financing.

The financial statements have been solely prepared for the management purpose.

These financial statements are presented in Indian Rupees, which is the Company's functional currency all amounts are rounded to the nearest thousand except when otherwise indicated.

Financial assets and financial liabilities are offset, and the net amount reported in financial position only when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liability simultaneously. Income and expense are not offset in the statement of profit or loss unless required or permitted by any accounting standard or interpretation.

The financial statements provide comparative information in respect of the previous periods.

2.3 INSURANCE CONTRACTS

2.3.1 Insurance and reinsurance contracts classification

The Company issues insurance contracts in the normal course of business, under which it accepts significant insurance risk from its policyholders. As a general guideline, the Company determines whether it has significant insurance risk, by comparing benefits payable after an insured event with benefits payable if the insured event did not occur. Insurance contracts can also transfer financial risk. The Company issues health insurance to individuals and businesses. The Company does not issue any contracts with direct participating features.

2.3.2 Insurance and reinsurance contracts accounting treatment

2.3.2.1 Separating components from insurance and reinsurance contracts

The Company assesses its health insurance and reinsurance held contracts to determine whether they contain distinct components which must be accounted for under another IFRS instead of under IFRS 17. After separating any distinct components, the Company applies IFRS 17 to all remaining components of the (host) insurance contract. Currently, the Company's products do not include any distinct components that require separation.

2.3.2.2 Level of aggregation

IFRS 17 requires a Company to determine the level of aggregation for applying its requirements. The level of aggregation for a Company is determined firstly by dividing the business written into portfolios. Portfolios comprise groups of contracts with similar risks which are managed together. Portfolios are further divided based on expected profitability at inception.



into three categories: onerous contracts, contracts with no significant risk of becoming onerous, and the remainder. IFRS 17 also requires that no group for level of aggregation purposes may contain contracts issued more than one year apart.

The Company has identified Retail and Group as its portfolio and it is divided into the underwriting cohorts to ensure contracts within a cohort are not issued one year apart.

The Company writes health business, including personal accident and travel to both retail and group segment. Since these includes morbidity risk, the risks are of similar nature for each portfolio.

Retail business is typically underwritten upfront and offers guaranteed lifelong renewability. Risk in retail business is not priced individually. Whereas, group business is generally more open with almost no or less underwriting, with no guaranteed renewability. Risks in group business are always priced individually. The underwriting process of the group and retail policies are different. Thus, retail and group businesses are managed differently.

Therefore, retail and group are identified portfolios.

IFRS 17 requires that no group of contracts contain contracts that are issued more than one year apart. Therefore, portfolio of contracts is divided into annual 'cohorts'. Annual underwriting Cohorts refers to the financial year, i.e., contracts that are issued from April 01 to March 31 of each financial year will be grouped together in a single underwriting cohort.

IFRS 17 requires contracts are required to be classified into groups according to the degree of profitability at initial recognition, which at a minimum include the following:

- A group of contracts that are onerous at initial recognition, if any;
- A group of contracts that at initial recognition have no significant possibility of becoming onerous, if any; and
- A group of remaining contracts in the portfolio, if any ('other').

The Company considers facts and circumstances to identify whether a group of contracts are onerous based on:

- Pricing information
- Results of similar contracts it has recognised
- Environmental factors, e.g., a change in market experience or regulations

The Company assumes that no contracts in the portfolio are onerous at initial recognition unless facts and circumstances indicate otherwise.

The Company divides portfolios of reinsurance contracts held applying the same principles set out above, except that the references to onerous contracts refer to contracts on which there is a net gain on initial recognition. The Company has divided the reinsurance at the least granular level of aggregation for the reinsurance contracts held i.e. at the reinsurance treaty.

2.3.2.3 Recognition

The Company recognises groups of insurance contracts it issues from the earliest of the following:

- The beginning of the coverage period of the group of contracts
- The date when the first payment from a policyholder in the group is due or when the first payment is received if there is no due date
- For a group of onerous contracts, if facts and circumstances indicate that the group is onerous

The Company recognises a group of reinsurance contracts held it has entered into from the earlier of the following:

- The beginning of the coverage period of the group of reinsurance contracts held. However, the Company delays the recognition of a group of reinsurance contracts held that provide proportionate coverage until the date any underlying insurance contract is initially recognised, if that date is later than the beginning of the coverage period of the group of reinsurance contracts held.

And

- The date the Company recognises an onerous group of underlying insurance contracts if the Company entered into the related reinsurance contract held in the group of reinsurance contracts held at or before that date.



The Company adds new contracts to the group in the reporting period in which that contract meets one of the criteria set out above.

2.3.2.4 Contract boundary

The Company includes in the measurement of a group of insurance contracts all the future cash flows within the boundary of each contract in the group. Cash flows are within the boundary of an insurance contract if they arise from substantive rights and obligations that exist during the reporting period in which the Company can compel the policyholder to pay the premiums, or in which the Company has a substantive obligation to provide the policyholder with insurance contract services.

A substantive obligation to provide insurance contract services ends when:

- The Company has the practical ability to reassess the risks of the particular policyholder and, as a result, can set a price or level of benefits that fully reflects those risks

Or

- Both of the following criteria are satisfied:
 - The Company has the practical ability to reassess the risks of the portfolio of insurance contracts that contain the contract and, as a result, can set a price or level of benefits that fully reflects the risk of that portfolio
 - The pricing of the premiums up to the date when the risks are reassessed does not take into account the risks that relate to periods after the reassessment date

A liability or asset relating to expected premiums or claims outside the boundary of the insurance contract is not recognised. Such amounts relate to future insurance contracts.

2.3.2.5 Measurement - Premium Allocation Approach

		IFRS 17 Options	Adopted approach
Premium Approach Eligibility	Allocation (PAA)	Subject to specified criteria, the PAA can be adopted as a simplified approach to the IFRS 17 general model	Contracts with coverage period one year or less automatically qualify for PAA. For contracts with coverage period greater than one-year PAA eligibility testing is done and there is no material difference in the measurement of the liability for remaining coverage between PAA and the General Measurement Model (GMM), therefore, these qualify for PAA.
Insurance acquisition cash flows for insurance contracts issued		Where the coverage period of all contracts within a group is no longer than one year, insurance acquisition cash flows can either be expensed as incurred, or allocated, using a systematic and rational method, to groups of insurance contracts (including future groups containing insurance contracts that are expected to arise from renewals) and then amortised over the coverage period of the related group. For groups containing contracts longer than one year, insurance acquisition cash flows must be allocated to related groups of insurance contracts and amortised over the coverage period of the related group.	Insurance acquisition cash flows are allocated to related groups of insurance contracts and amortised over the coverage period of the related group.
Liability for Remaining Coverage (LFRC), adjusted for financial risk and time value of money		Where there is no significant financing component in relation to the LFRC, or where the time between providing each part of the services and the related premium due date is no more than a year, an entity is not required to make an adjustment for accretion of interest on the LFRC.	There is no allowance for accretion of interest on the LFRC as there is no significant financing component.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Notes to the Financial Statements

Liability for Incurred Claims, (LIC) adjusted for time value of money	Where claims are expected to be paid within a year of the date that the claim is incurred, it is not required to adjust these amounts for the time value of money.	As majority of the incurred claims are expected to be paid out in less than one year hence no adjustment is made for time value of money.
Insurance finance income and expense	There is an option to disaggregate part of the movement in LIC resulting from changes in discount rates and present this in OCI.	Not applicable as there is no discounting.

2.3.2.6 Insurance contracts – initial measurement

The Company applies the premium allocation approach (PAA) to all the insurance contracts that it issues and reinsurance contracts that it holds, as:

- The coverage period of each contract in the group is one year or less, including insurance contract services arising from all premiums within the contract boundary (refer Note 2.3.2.4)

Or

- For contracts longer than one year, the Company has modelled possible future scenarios and reasonably expects that the measurement of the liability for remaining coverage for the group containing those contracts under the PAA does not differ materially from the measurement that would be produced applying the general model. In assessing materiality, the Company has also considered qualitative factors such as the nature of the risk and types of its lines of business.

The Company does not apply the PAA if, at the inception of the group of contracts, it expects significant variability in the fulfilment cash flows that would affect the measurement of the liability for the remaining coverage during the period before a claim is incurred.

For a group of contracts that is not onerous at initial recognition, the Company measures the liability for remaining coverage as:

- Unearned premium reserve for the unexpired policy basis 1/365th method
- Minus acquisition cost deferred for the unexpired term of the policies
- Plus, any Freelook cancellation reserve

There is no allowance for time value of money as majority of the premiums are received within one year of the coverage period.

Where facts and circumstances indicate that contracts are onerous at initial recognition, the Company performs additional analysis to determine if a net outflow is expected from the contract. Such onerous contracts are separately grouped from other contracts and the Company recognises a loss in profit or loss for the net outflow, resulting in the carrying amount of the liability for the group being equal to the fulfilment cash flows. A loss component is established by the Company for the liability for remaining coverage for such onerous group depicting the losses recognised. For additional disclosures on the loss component, please refer to Note 2.3.2.14.

2.3.2.7 Reinsurance contracts held – initial measurement

The Company measures its reinsurance assets for a group of reinsurance contracts that it holds on the same basis as insurance contracts that it issues. However, they are adapted to reflect the features of reinsurance contracts held that differ from insurance contracts issued, for example the generation of expenses or reduction in expenses rather than revenue.

Where the Company recognises a loss on initial recognition of an onerous group of underlying insurance contracts or when further onerous underlying insurance contracts are added to a group, the Company establishes a loss-recovery component of the asset for remaining coverage for a group of reinsurance contracts held depicting the recovery of losses.

The Company calculates the loss-recovery component by multiplying the loss recognised on the underlying insurance contracts and the percentage of claims on the underlying insurance contracts the Company expects to recover from the group of reinsurance contracts held. The Company uses a systematic and rational method to determine the portion of losses recognised on the group to insurance contracts covered by the group of reinsurance contracts held where some contracts in the underlying group are not covered by the group of reinsurance contracts held.



The loss-recovery component adjusts the carrying amount of the asset for remaining coverage.

2.3.2.8 Insurance contracts – subsequent measurement

The Company measures the carrying amount of the liability for remaining coverage at the end of each reporting period as the liability for remaining coverage at the beginning of the period:

- Plus premiums received in the period
- Minus insurance acquisition cash flows
- Plus any amounts relating to the amortisation of the insurance acquisition cash flows recognised as an expense in the reporting period for the group
- Plus any adjustment to the financing component, where applicable
- Minus the amount recognised as insurance revenue for the services provided in the period
- Minus any investment component paid or transferred to the liability for incurred claims

The Company estimates the liability for incurred claims as the fulfilment cash flows related to incurred claims. The fulfilment cash flows incorporate, in an unbiased way, all reasonable and supportable information available without undue cost or effort about the amount, timing and uncertainty of those future cash flows, they reflect current estimates from the perspective of the Company, and include an explicit adjustment for non-financial risk (the risk adjustment). The Company does not adjust the future cash flows for the time value of money and the effect of financial risk for the measurement of liability for incurred claims as majority are expected to be paid within one year of being incurred.

Insurance acquisition cash flows are allocated on a straight-line basis as a portion of premium to profit or loss (through insurance revenue).

2.3.2.9 Reinsurance contracts held – subsequent measurement

The subsequent measurement of reinsurance contracts held follows the same principles as those for insurance contracts issued and has been adapted to reflect the specific features of reinsurance held.

Where the Company has established a loss-recovery component, the Company subsequently reduces the loss recovery component to zero in line with reductions in the onerous group of underlying insurance contracts in order to reflect that the loss-recovery component shall not exceed the portion of the carrying amount of the loss component of the onerous group of underlying insurance contracts that the entity expects to recover from the group of reinsurance contracts held.

2.3.2.10 Insurance acquisition cash flows

Insurance acquisition cash flows arise from the costs of selling, underwriting and starting a group of insurance contracts (issued or expected to be issued) that are directly attributable to the portfolio of insurance contracts to which the group belongs.

The Company uses a systematic and rational method to allocate:

- i. Insurance acquisition cash flows that are directly attributable to a group of insurance contracts to that group
- ii. Insurance acquisition cash flows directly attributable to a portfolio of insurance contracts that are not directly attributable to a group of contracts, to groups in the portfolio.

Where insurance acquisition cash flows have been paid or incurred before the related group of insurance contracts is recognised in the statement of financial position, a separate asset for insurance acquisition cash flows is recognised for each related group.

The asset for insurance acquisition cash flow is derecognised from the statement of financial position when the insurance acquisition cash flows are included in the initial measurement of the related group of insurance contracts.

At the end of each reporting period, the Company revises amounts of insurance acquisition cash flows allocated to groups of insurance contracts not yet recognised, to reflect changes in assumptions related to the method of allocation used.

After any re-allocation, the Company assesses the recoverability of the asset for insurance acquisition cash flows, if facts and circumstances indicate the asset may be impaired. When assessing the recoverability, the Company applies:

- An impairment test at the level of an existing or future group of insurance contracts; and
- An additional impairment test specifically covering the insurance acquisition cash flows allocated to expected future contract renewals.



If an impairment loss is recognised, the carrying amount of the asset is adjusted and an impairment loss is recognised in profit or loss.

The Company recognises in statement of profit or loss a reversal of some or all of an impairment loss previously recognised and increases the carrying amount of the asset, to the extent that the impairment conditions no longer exist or have improved.

2.3.2.11 Insurance contracts – modification and derecognition

The Company derecognises insurance contracts when:

- The rights and obligations relating to the contract are extinguished (i.e., discharged, cancelled or expired)
- The contract is modified such that the modification results in a change in the measurement model or the applicable standard for measuring a component of the contract, substantially changes the contract boundary, or requires the modified contract to be included in a different group. In such cases, the Company derecognises the initial contract and recognises the modified contract as a new contract

When a modification is not treated as a derecognition, the Company recognises amounts paid or received for the modification with the contract as an adjustment to the relevant liability for remaining coverage.

2.3.2.12 Presentation

The Company has presented separately, in the statement of financial position, the carrying amount of portfolios of insurance contracts issued that are assets, portfolios of insurance contracts issued that are liabilities, portfolios of reinsurance contracts held that are assets and portfolios of reinsurance contracts held that are liabilities.

Any assets for insurance acquisition cash flows recognised before the corresponding insurance contracts are included in the carrying amount of the related groups of insurance contracts are allocated to the carrying amount of the portfolios of insurance contracts that they relate to.

The Company disaggregates the total amount recognised in the statement of profit or loss and other comprehensive income into an insurance service result, comprising insurance revenue and insurance service expense, and insurance finance income or expenses.

The Company does not disaggregate the change in risk adjustment for non-financial risk between a financial and non-financial portion and includes the entire change as part of the insurance service result.

The Company separately presents income or expenses from reinsurance contracts held from the expenses or income from insurance contracts issued.

2.3.2.13 Insurance revenue

The insurance revenue for the period is the amount of expected premium receipts (excluding any investment component if any) allocated to the period. The Company allocates the expected premium receipts to each period of insurance contract services on the basis of the passage of time. But if the expected pattern of release of risk during the coverage period differs significantly from the passage of time, then the allocation is made on the basis of the expected timing of incurred insurance service expenses.

The Company changes the basis of allocation between the two methods above as necessary, if facts and circumstances change. The change is accounted for prospectively as a change in accounting estimate.

For the periods presented, all revenue has been recognised on the basis of the passage of time.

2.3.2.14 Loss components

The Company assumes that no contracts are onerous at initial recognition unless facts and circumstances indicate otherwise. Where this is not the case, and if at any time during the coverage period, the facts and circumstances mentioned in Note 2.3.2.2 indicate that a group of insurance contracts is onerous, the Company establishes a loss component as the excess of the fulfilment cash flows that relate to the remaining coverage of the group over the carrying amount of the liability for remaining coverage of the group as determined in Note 2.3.2.8. Accordingly, by the end of the coverage period of the group of contracts the loss component will be zero.



2.3.2.15 Loss-recovery components

As described in Note 2.3.2.7 above, where the Company recognises a loss on initial recognition of an onerous group of underlying insurance contracts, or when further onerous underlying insurance contracts are added to a group, the Company establishes a loss-recovery component of the asset for remaining coverage for a group of reinsurance contracts held depicting the expected recovery of the losses.

A loss-recovery component is subsequently reduced to zero in line with reductions in the onerous group of underlying insurance contracts in order to reflect that the loss-recovery component shall not exceed the portion of the carrying amount of the loss component of the onerous group of underlying insurance contracts that the entity expects to recover from the group of reinsurance contracts held.

2.3.2.16 Insurance finance income and expense

Insurance finance income or expenses comprise the change in the carrying amount of the group of insurance contracts arising from:

- The effect of the time value of money and changes in the time value of money; and
- The effect of financial risk and changes in financial risk.

There are no such contracts which are eligible for insurance finance income and expense.

2.4 FINANCIAL INSTRUMENTS

2.4.1 Initial recognition

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities is initially measured at fair value plus or minus, for an item not at FVTPL, transaction costs that are directly attributable to its acquisition or issue.

2.4.2 Subsequent measurement

2.4.2.1 Non-derivative financial instruments

2.4.2.1.1 Financial assets at amortised cost

A financial asset is subsequently measured at amortised cost if it is held within a business where the objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

2.4.2.1.2 Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business where the objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company has made an election for its investments which are classified as debt instruments and bonds to present the subsequent changes in fair value in other comprehensive income based on its business model.

2.4.2.1.3 Financial assets at fair value through profit or loss (FVTPL)

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

2.4.2.2 Financial liabilities

Financial liabilities are subsequently carried at amortized cost using the effective interest method. For other liabilities maturing within one year from the statement of financial position date, the carrying amounts approximate fair value due to the short maturity of these instruments.

2.4.3 Derecognition of financial instruments

2.4.3.1 Derecognition of financial assets

A financial asset is primarily derecognised when:

the rights to receive cash flows from the asset have expired, or



• The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

2.4.3.2 Derecognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in the statement of profit or loss.

2.4.4 Fair value of financial instruments

Fair value hierarchy:

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

2.4.5 Recognition of interest income

2.4.5.1 The effective interest rate method

Under IFRS 9, interest income is recorded using the effective interest rate (EIR) method for all financial assets measured at amortised cost. Similar to interest bearing financial assets previously classified as available-for-sale or held to maturity under IAS 39, interest income on interest bearing financial assets measured at FVTOCI under IFRS 9 is also recorded using the EIR method. The EIR is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset or, when appropriate, a shorter period, to the gross carrying amount of the financial asset.

The EIR (and therefore, the amortised cost of the financial asset) is calculated by taking into account transaction costs and any discount or premium on acquisition of the financial asset as well as fees and costs that are an integral part of the EIR. The Company recognises interest income using a rate of return that represents the best estimate of a constant rate of return over the expected life of the debt instrument.

If expectations of a fixed rate financial asset's cash flows are revised for reasons other than credit risk, and the changes to future contractual cash flows are discounted at the original EIR with a consequential adjustment to the carrying amount. The difference to the previous carrying amount is booked as a positive or negative adjustment to the carrying amount of the financial asset in the statement of financial position with a corresponding increase or decrease in interest income.

For floating-rate financial instruments, periodic re-estimation of cash flows to reflect the movements in the market rates of interest also alters the effective interest rate, but when instruments were initially recognised at an amount equal to the principal, re-estimating the future interest payments does not significantly affect the carrying amount of the asset or the liability.



2.5. INSURANCE AND FINANCIAL RISK

2.5.1 Insurance risk

2.5.1.1 Insurance contracts issued and reinsurance contracts held

The Company principally issues health insurance contract which include personal accident, critical illness and travel.

The objective of the Company is to ensure that sufficient reserves are available to cover the liabilities associated with these insurance contracts issued and reinsurance contracts held. The risk exposure is mitigated by diversification across the portfolios of insurance contracts. The variability of risks is also improved by careful selection and implementation of underwriting strategy guidelines, as well as the use of reinsurance held arrangements. Furthermore, strict claim review policies to assess all new and ongoing claims, regular detailed review of claims handling procedures and frequent investigation of possible fraudulent claims are established to reduce the risk exposure of the Company. The Company further enforces a policy of actively managing and promptly settling claims, in order to reduce its exposure to unpredictable future developments that can negatively impact the business. Inflation risk is mitigated by taking expected inflation into account when estimating insurance contract liabilities and pricing appropriately.

The Company purchases reinsurance as part of its risk mitigation programme. Reinsurance held is placed on a proportional as well non-proportional basis. Proportional reinsurance is quota-share reinsurance and surplus reinsurance. Non-proportional reinsurance is CAT-XOL for personal accident business.

Amounts recoverable from reinsurers are estimated in a manner consistent with underlying insurance contract liabilities and in accordance with the reinsurance contracts. Although the Company has reinsurance arrangements, it is not relieved of its direct obligations to its policyholders and thus a credit exposure exists with respect to reinsurance held, to the extent that any reinsurer is unable to meet its obligations. The Company's placement of reinsurance is diversified such that it is neither dependent on a single reinsurer nor are the operations of the Company substantially dependent upon any single reinsurance contract.

2.5.1.2 Sensitivities

The liability for incurred claims is sensitive to the key assumptions in the table below. It has not been possible to quantify the sensitivity of certain assumptions such as legislative changes or uncertainty in the estimation process.

The sensitivity analysis shows the impact on gross and net liabilities, profit before tax and equity for reasonably possible movements in key assumptions with all other assumptions held constant using stress testing methodology (refer Note 29.2). The correlation of assumptions will have a significant effect in determining the ultimate impacts, but to demonstrate the impact due to changes in each assumption, assumptions have been changed on an individual basis. It should be noted that movements in these assumptions are non-linear. The method used for deriving sensitivity information and significant assumptions did not change from the previous period.

2.5.1.3 Claims development table

As required by IFRS 17, in setting claims provisions, the Company gives consideration to the probability and magnitude of future experience being more adverse than assumed which is reflected in the risk adjustment. In general, the uncertainty associated with the ultimate cost of settling claims is greatest when the claim is at an early stage of development. As claims develop, the ultimate cost of claims becomes more certain.

The Company has not disclosed previously unpublished information about claims development that occurred earlier than five years before the end of the annual reporting period in which it first applies IFRS 17. (Refer Note 29.3 for details)

2.5.2 Financial risk

2.5.2.1 Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with insurance liabilities that are settled by delivering cash or another financial asset. In respect of catastrophic events, there is also a liquidity risk associated with the timing differences between gross cash outflows and expected reinsurance recoveries.

The following policies and procedures are in place to mitigate the Company's exposure to liquidity risk:

The Company's Asset Management Liability policy sets out the assessment and determination of what constitutes liquidity risk for the Company. Compliance with the policy is monitored and exposures and breaches are reported to the Company's risk committee. The policy is regularly reviewed for pertinence and for changes in the risk environment.



The Company maintains a portfolio of highly marketable and diverse assets that can be easily liquidated in the event of an unforeseeable interruption of cash flow. The Company also has committed lines of credit that it can access to meet liquidity needs.

2.5.2.2 Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument, insurance contract issued or reinsurance contract held will fluctuate because of changes in market prices. Market risk comprises three types of risk: foreign exchange rates (currency risk); market interest rates (interest rate risk); and market prices (price risk).

The Company's Asset Liability Management policy sets out the assessment and determination of what constitutes market risk for it. Compliance with the policy is monitored and exposures and breaches are reported to the Company's risk committee. The policy is reviewed regularly for pertinence and for changes in the risk environment.

Guidelines are set for asset allocation and portfolio limit structure, to ensure that assets back specific policyholders' liabilities and that assets are held to deliver income and gains needed to meet the Company's contractual requirements.

The nature of the Company's exposure to market risks and its objectives, policies and processes used to manage and measure the risks have not changed from the previous period.

2.5.2.3 Currency risk

Currency risk is the risk that the fair value of future cash flows of a financial instrument, insurance contract assets and/or liabilities will fluctuate because of changes in foreign exchange rates.

The Company's principal transactions are carried out in INR and its exposure to foreign exchange risk is minimal as it does not issue policies denominated in foreign currency nor its major expenses debt or investment assets are denominated in a foreign currency. The Company's financial assets are primarily denominated in the same currencies as its insurance contract liabilities.

2.5.2.4 Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument or insurance contract or reinsurance contract will fluctuate because of changes in market interest rates.

Floating rate instruments expose the Company to cash flow interest risk, whereas fixed interest rate instruments expose the Company to fair value interest rate risk.

There is no direct contractual relationship between financial assets and insurance contracts.

2.5.2.5 Price risk

Price risk is the risk that the fair value or future cash flows of financial instruments or insurance contract assets and/or liabilities will fluctuate because of changes in market prices (other than those arising from interest rate or foreign exchange rate risk), whether those changes are caused by factors specific to the individual financial instrument or contract, or by factors affecting all similar contracts or financial instruments traded in the market.

The Company's price risk exposure relates to financial assets and financial liabilities whose values will fluctuate as a result of changes in market prices. The Company does not issue any participating contracts. Therefore, there are no insurance or reinsurance contracts which are exposed to price risk.

The Company's price risk policy requires it to manage such risks by setting and monitoring objectives and constraints on investments, diversification plans, limits on individual and total equity instruments.

The Company has no significant concentration of price risk.

This analysis was performed for reasonably possible movements in the market index with all other variables held constant. The correlation of variables will have a significant effect in determining the ultimate impact on price risk, but to demonstrate the impact due to changes in variables, variables had to be changed on an individual basis. It should be noted that movements in these variables are non-linear. The method used for deriving sensitivity information and significant variables has not changed from the previous period.



2.5.2.6 Operational risks

Operational risk is the risk of loss arising from system failure, human error, fraud or external events. When controls fail to perform, operational risks can cause damage to reputation, have legal or regulatory implications or can lead to financial loss. The Company cannot expect to eliminate all operational risks, but by initiating a rigorous control framework and by monitoring and responding to potential risks, the Company is able to manage the risks. Controls include effective segregation of duties, access controls, authorisation and reconciliation procedures, staff education and assessment processes, including the use of internal audit. Business risks such as changes in environment, technology and the industry are monitored through the Company's strategic planning and budgeting process.

2.5.2.7 Credit risk

Credit risk is the risk that one party to a financial instrument, insurance contract issued in an asset position or reinsurance contract held will cause a financial loss for the other party by failing to discharge an obligation.

The following policies and procedures are in place to mitigate the Company's exposure to credit risk:

The Company's Asset Liability Management policy sets out the assessment and determination of what constitutes credit risk for the Company. Compliance with the policy is monitored and exposures and breaches are reported to the Company's risk committee. The policy is regularly reviewed for pertinence and for changes in the risk environment.

Credit risk relating to financial instruments is monitored by the Company's mid office investment team. They review and manage credit risk, including environmental risk for all counterparties. The Company manages and controls credit risk by setting limits on the amount of risk it is willing to accept for individual counterparties and for geographical and industry concentrations, and by monitoring exposures in relation to such limits. It is the Company's policy to invest in high quality financial instruments with a low risk of default. If there is a significant increase in credit risk, the policy dictates that the instrument should be sold and amounts recovered reinvested in high quality instruments.

There is no allowance for credit risk on the insurance premium receivable because the premium is paid in advance before the commencement of the risk. This is also mandated by the local regulations (i.e. the risk cannot commence unless premium is received).

Reinsurance is placed with counterparties that have a good credit rating and concentration of risk is avoided by following policy guidelines in respect of counterparty's limits that are set each year by the board of directors and are subject to regular reviews. At each reporting date, management performs an assessment of creditworthiness of reinsurers and updates the reinsurance purchase strategy.

Receivables on account of accrued interest is on the investment held by the Company. The investments are held with a high credit rating and is monitored on the periodic basis to avoid the credit risk. At each reporting date, management performs an assessment of creditworthiness of investments and updates the investment policy accordingly. The assessment of the credit risk from other receivables is based on internal expert assessments. In addition to monitoring credit risk, the Company have implemented continuous monitoring of financial investments on the basis of internal and external credit ratings.

The credit risk in respect of customer balances incurred on non-payment of premiums will only persist during the grace period specified in the policy document. Commission paid to intermediaries is netted off against amounts receivable from them to reduce the risk of default.

The nature of the Company's exposure to credit risk and its objectives, policies and processes used to manage and measure the risks have not changed from the previous period.

2.5.2.7.1 The Company's internal rating process

The Company's investment team prepares a credit assessment note for each issuer wherein the funds are to be invested. The note incorporates both qualitative and quantitative information that builds on information from an external Credit rating agency, supplemented with information specific to the counterparty and other external information that could affect the counterparty's behaviour. All the issuers wherein Company seeks to invest are approved by the Investment Committee.

2.5.2.7.2 Impairment assessment - Significant increase in credit risk, default and cure

The Company's ECL assessment and measurement method is set out below.

The Company recognises loss allowances for ECLs on:
financial assets measured at amortised cost and



- debt securities measured at FVOCI (Refer Note 4 of the financial statements)

The Company measures loss allowances at an amount equal to lifetime ECLs, except for the following, which are measured at 12-month ECLs:

- debt securities that are determined to have low credit risk at the reporting date; and
- other debt securities for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis, based on the Company's historical experience and informed credit assessment, that includes forward-looking information. Refer Note 2.5.2.7 for further details.

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 90 days past due. The Company considers a financial asset to be in default when:

- the debtor is unlikely to pay its credit obligations to the Company in full, without recourse by the Company to actions such as realising security (if any is held); or
- the financial asset is more than 90 days past due.

The Company considers a debt security to have low credit risk when its credit risk rating is equivalent to the globally understood definition of 'investment grade'. The Company considers this to be AAA as per [Rating Agency CRISIL, CARE and FITCH] or LAAB as per [Rating Agency ICRA]."

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument

2.6. CAPITAL

2.6.1 Capital management objectives, policies and approach

The Company has established the following capital management objectives, policies and approach to managing the risks that affect its capital position:

- To maintain the required level of stability of the Company thereby providing a degree of security to policyholders
- To allocate capital efficiently and support the development of business by ensuring that returns on capital employed meet the requirements of its capital providers and shareholders
- To retain financial flexibility by maintaining strong liquidity and access to a range of capital markets
- To align the profile of assets and liabilities, taking account of risks inherent in the business
- To maintain financial strength to support new business growth and to satisfy the requirements of the policyholders, regulators and stakeholders
- To maintain strong credit ratings and healthy capital ratios in order to support its business objectives and maximise shareholders value

The Company is also subject to regulatory requirements within the jurisdictions in which it operates. Such regulations not only prescribe approval and monitoring of activities, but also impose certain restrictive provisions (e.g., capital adequacy) to minimise the risk of default and insolvency on the part of the insurance companies to meet unforeseeable liabilities as they arise.

The Company has met all of these requirements throughout the financial year.

In reporting financial strength, capital and solvency are measured using the rules prescribed by the IRDAI.

The Company's capital management policy is to hold sufficient capital to cover the statutory requirements based on the IRDAI Regulations.

In determining groups of contracts, the Company has elected to include in the same group contracts where the Company's ability to set prices or levels of benefits for policyholders with different characteristics is constrained by regulation.

Approach to capital management

The Company seeks to optimise the structure and sources of capital to ensure that it consistently maximises returns to the shareholders.



The Company's approach to managing capital involves managing assets, liabilities and risks in a coordinated way, assessing shortfalls between reported and required capital levels on a regular basis and taking appropriate actions to influence the capital position of the Company in the light of changes in economic conditions and risk characteristics. An important aspect of the Company's overall capital management process is the setting of target risk adjusted rates of return, which are aligned to performance objectives and ensure that the Company is focused on the creation of value for shareholders.

The primary source of capital used by the Company is total equity. The Company also uses other forms of capital such as debt, in addition to more traditional sources of funding.

The capital requirements are routinely forecast on a periodic basis and assessed against both the forecast available capital and the expected internal rate of return, including risk and sensitivity analyses. The process is ultimately subject to approval by the Board.

The Company has made no significant changes, from previous years, to its policies and processes for its capital structure.

2.7 SIGNIFICANT JUDGEMENTS AND ESTIMATES

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur. The Company disaggregates information over retail and group business segments. This disaggregation has been determined based on how the Company is managed.

2.7.1 Insurance contracts issued and reinsurance contracts held

The Company applies the PAA to simplify the measurement of insurance contracts.

2.7.1.1 Liability for remaining coverage

Insurance acquisition cash flows

Insurance acquisition cash flows are allocated to related groups of insurance contracts recognised in the statement of financial position, below are the key judgements used:

- a) **Identifying Direct Costs:** Distinguishing acquisition costs directly tied to new contracts from general administrative expenses.
- b) **Grouping Contracts:** Deciding how to group contracts based on risk and profitability, which affects cost allocation and amortization.
- c) **Estimating Fulfilment Cash Flows:** Setting assumptions for future premiums, claims, and other cash flows that impact acquisition costs.
- d) **Allocating Costs Across Products:** Allocating acquisition costs when they relate to multiple products or lines of business.

These judgments affect how acquisition costs are recognized, measured, and reported.

Onerous groups

Onerous contracts shall be grouped separately and its liability for remaining coverage is determined by the fulfilment cash flows. Any loss-recovery component is determined with reference to the loss component recognised on underlying contracts and the recovery expected on such claims from reinsurance contracts held. For LIC, the computation is consistent across measurement models as expected cashflows adjusted for time value of money, if required and a risk adjustment.

2.7.1.2 Liability for incurred claims

The ultimate cost of outstanding claims is estimated by using a range of standard actuarial claims projection techniques, such as Chain Ladder and Bornheutter-Ferguson methods.

The main assumption underlying these techniques is that a Company's past claims development experience can be used to project future claims development and hence ultimate claims costs. These methods extrapolate the development of paid and incurred losses based on the observed development of earlier years and expected loss ratios. Historical claims



development is mainly analysed by accident years, as well as by significant business lines and claim types. Large claims are usually separately addressed, either by being reserved at the face value of loss adjuster estimates or separately projected in order to reflect their future development. In most cases, no explicit assumptions are made regarding future rates of claims inflation or loss ratios. Instead, the assumptions used are those implicit in the historical claims development data on which the projections are based. Additional qualitative judgement is used to assess the extent to which past trends may not apply in future, (e.g., to reflect one-off occurrences, changes in external or market factors economic conditions, levels of claims inflation, judicial decisions and legislation, as well as internal factors such as portfolio mix, policy features and claims handling procedures) in order to arrive at the estimated ultimate cost of claims that present the probability weighted expected value outcome from the range of possible outcomes, taking account of all the uncertainties involved.

Time value of money

There is no adjustment for the time value of money because majority of the claims are settled within 12 months. Claims settled beyond 12 months are not expected to be material.

2.7.1.3 Discount rates

IFRS 17 requires that the discount rate with respect to contractual cash flows that do not vary based on the returns on underlying items, either a Bottom-up and Top-down approach can be used. Under a bottom-up approach, the discount rate is based on a liquid risk-free yield curve then an addition is made to reflect the relative illiquidity of the insurance contracts. However, the top-down approach is based on yield-curve that reflects the current market rate of returns of a reference portfolio of assets adjusted to eliminate any factors that are not relevant to the insurance contracts (e.g., credit risk)

The Company chooses to adopt a bottom-up approach to derive the discount rates for liability valuation.

The risk-free rate takes into account the time value of money and does not consider non-insurance risks. In India, Risk free rates are based on the Zero-Coupon Sovereign Rupee Yield Curve (ZCYC) curve supplied by the Fixed Income Money Market and Derivatives Association of India (FIMMDA) website.

The Company's underlying insurance contract does have cancellation feature and hence the policyholder can exit the policy via expiry of term or cancellation. Further, owing to the short-term nature of the contract where majority of the business is two years or less, the contract is identified to be liquid from a policyholder's standpoint as they are free to switch insurers once the policy term ends. Hence, the illiquidity premium is not applied while computing discount rates for the underlying groups.

For the ceded reinsurance groups, the Company can exit the treaties except Obligatory reinsurance treaty; giving a notice of three months subject to term and conditions mentioned in the treaties, the policies reinsured before cancellation will continue to be reinsured by the prevailing reinsurer unless a recapture clause is applied. Owing to the ease of exit, the Reinsurance treaties are also identified as liquid and hence illiquidity premium is not added to discount rates for ceded groups as well.

2.7.1.4 Risk adjustment for non-financial risk

The risk adjustment for non-financial risk is the compensation that the Company requires for bearing the uncertainty about the amount and timing of the cash flows of groups of insurance contracts. The risk adjustment reflects an amount that an insurer would rationally pay to remove the uncertainty that future cash flows will exceed the expected value amount.

The company estimated the risk adjustment using a confidence level approach at the 85th percentile (2024 – 85th percentile) which is in line with the company's risk appetite for the uncertainty in the claims and related expenses, and any movements in the risk adjustment are recognised in full within the insurance service result.

2.7.1.5 Assets for insurance acquisition cash flows

The Company applies judgement in determining the inputs used in the methodology to systematically and rationally allocate insurance acquisition cash flows to groups of insurance contracts.

At the end of each reporting period, the Company revisits the assumptions made to allocate insurance acquisition cash flows to groups and where necessary revises the amounts of assets for insurance acquisition cash flows accordingly.

In the current and prior year, for other product lines, the Company did not identify any facts and circumstances indicating that the assets may be impaired.



2.7.2 Impairment on financial assets

The key parameters for calculating Expected Credit Losses (ECL) are the probability of default, the loss given default and the exposure at default.

The probability of default is the basis for specifying a stage of the impairment model. In addition, the probability of default is considered whenever ECL are calculated. During our internal rating process, the probability of default is calculated on the basis of historical data, current market conditions, and assumptions about the future.

The loss given default and the exposure at default are likewise factored into calculations of ECL. In this context, the loss given default is derived from the recovery and default studies published by rating agencies. The exposure at default corresponds to the gross carrying amount as at the reporting date.

2.7.3 Provision and contingent liability

On an ongoing basis, the Company reviews pending cases, claims by third parties and other contingencies. For contingent losses that are considered probable, an estimated loss is recorded as an accrual in financial statements. Loss Contingencies that are considered possible are not provided for but disclosed as Contingent liabilities in the financial statements. Contingencies the likelihood of which is remote are not disclosed in the financial statements. Gain contingencies are not recognized until the contingency has been resolved and amounts are received or receivable.

2.7.4 Share based payment

Estimating fair value for share based payment requires determination of the most appropriate valuation model. The estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share based payments transactions are disclosed in Note 20.3 "Share based payment".

2.7.5 Defined Benefit Plan

The cost of the defined benefit plans and the present value of the defined benefit obligation are based on actuarial valuation using the projected unit credit method. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date and are disclosed in Note 20.1 "Gratuity - Defined benefit plan".

2.7.6 Business model assessment

Classification and measurement of financial assets depends on the results of the SPPI and the business model test. The Company determines the business model at a level that reflects how groups of financial assets are managed together to achieve a particular business objective. This assessment includes judgement reflecting all relevant evidence including how the performance of the assets is evaluated and their performance measured, the risks that affect the performance of the assets and how these are managed and how the managers of these assets are compensated.

Monitoring is part of the Company's continuous assessment of whether the business model for which the financial assets are held continues to be appropriate and if it is not appropriate, whether there has been a change in business model and so a prospective change to the classification of those assets.

2.8 INCOME TAXES

Income tax expense comprises current and deferred income tax. Income tax expense is recognized in the statement of profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive income.

Current income tax for current and prior periods is recognized at the amount expected to be paid to or recovered from the tax authorities, using the tax rates and tax laws that have been enacted.

Deferred income tax assets and liabilities are recognized for all temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Deferred tax assets are recognised for unused tax losses, unabsorbed depreciation and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Future taxable



profits are determined based on the reversal of relevant taxable temporary differences. If the amount of taxable temporary differences is insufficient to recognise a deferred tax asset in full, then future taxable profits, adjusted for reversals of existing temporary differences, are considered, based on the business plans of the Company. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves.

Deferred income tax assets and liabilities are measured using tax rates and tax laws that have been enacted or substantively enacted by the reporting date and are expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect of changes in tax rates on deferred income tax assets and liabilities is recognized as income or expense in the period that includes the enactment or the substantive enactment date. The Company offsets tax assets and tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

2.9 PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of property, plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied.

All other repair and maintenance costs are recognised in statement of profit or loss and other comprehensive income as incurred. The Company identifies and determines cost of each component/ part of property, plant and equipment separately, if the component/ part has a cost which is significant to the total cost of the property, plant and equipment and has useful life that is materially different from that of the remaining asset.

Depreciation on property, plant and equipment is provided based on straight line method using the rates basis the economic useful life of assets as estimated by the management which reflects the useful life specified in Schedule II of the Companies Act, 2013, as follows:

Useful lives estimated by the management in years:

Leasehold improvements	Lease period
Furniture and fixtures	5 years
Office equipments	5 years
Information Technology equipment	3 years
- End User Devices	
Information Technology equipment	4 years
- Servers and Networks	
Intangibles (including Software)	4 years

Depreciation methods, useful lives and residual values are reviewed periodically, including at each financial year end.

Gains or losses arising from de-recognition of property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss and other comprehensive income when the asset is derecognised.

2.10 CAPITAL WORK-IN PROGRESS

Capital work-in progress (CWIP) comprises of property, plant and equipment that are not ready for their intended use at the end of reporting period. CWIP is measured at cost comprising direct costs, related incidental expenses, other directly attributable costs and borrowing costs.

The cost of CWIP shall be recognised as an asset only if the recognition criteria are met. CWIP is derecognised when the construction and installation are complete and the asset is ready for its intended use. CWIP is not depreciated until it is available for intended use.

2.11 INTANGIBLE ASSETS

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangible assets, including capitalised development costs, are not capitalised and the related expenditure is reflected in the



statement of profit or loss and other comprehensive income in the period in which the expenditure is incurred. The estimated useful life of assets are as follows:

Useful lives estimated by the management in years:

Intangibles (including Software)	4 years
----------------------------------	---------

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit or loss and other comprehensive income unless such expenditure forms part of carrying value of another asset.

Gains or losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss and other comprehensive income when the asset is derecognised.

2.12 IMPAIRMENT

2.12.1 Financial assets

Financial assets (other than at fair value)

The Company assesses at each reporting date whether a financial asset or a group of financial assets is impaired. IFRS 9 ('Financial Instruments') requires ECL to be measured through a loss allowance.

2.12.2 Non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or group of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset. An impairment loss is reversed in the statement of income if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

2.13 PROVISIONS & CONTINGENT LIABILITY

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are measured at the best estimate of the expenditure required to settle the present obligation at the Balance Sheet date.

If the effect of the time value of money is material, provisions are discounted to reflect its present value using a current pre-tax rate that reflects the current market assessment of the time value of money and the risks specific to the obligation. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control



of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made.

2.14 EARNINGS PER SHARE (EPS)

Basic earnings per equity share is computed by dividing the net profit attributable to the equity holders of the Company by the weighted average number of equity shares outstanding during the period. Diluted earnings per equity share is computed by dividing the net profit attributable to the equity holders of the Company by the weighted average number of equity shares considered for deriving basic earnings per equity share and also the weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. The dilutive potential equity shares are adjusted for the proceeds receivable had the equity shares been actually issued at fair value (i.e. the average market value of the outstanding equity shares). Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

2.15 EMPLOYEE BENEFITS

2.15.1 Gratuity - Defined benefit plans

The present value of the obligation under defined benefit plans are determined based on actuarial valuation using the Projected Unit Credit Method. In case of funded plans, the fair value of the plan assets is reduced from the gross obligation under the defined benefit plans to recognize the obligation on a net basis.

In case of defined benefit plans, remeasurement comprising of actuarial gains and losses is recognized in other comprehensive income (OCI) and is reflected in retained earnings and is not eligible to be reclassified to profit or loss.

The Company recognises the following changes in the net defined benefit obligation as an expense in statement of profit and loss:

- Service cost including current service cost, past service cost and gains and losses on curtailments and settlements; and
- Net interest expense or income.

2.15.2 Defined contribution plans

The Company contributes to a recognised Provident Fund and State Insurance which is a defined contribution plan. The contributions are accounted for on an accrual basis and recognised in the statement of profit or loss.

2.15.3 Compensated absences

Accumulated leave, which is expected to be utilised within the next 12 months, is treated as short-term employee benefits. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date. Deferred compensation, which is a long-term employee benefit, is provided for based on the independent actuarial valuation carried out as at the reporting date and charged to statement of profit or loss and other comprehensive income based on services rendered by employees.

2.15.4 Share based payment

The Company recognizes compensation expense relating to share-based payments in net profit using fair-value in accordance with IFRS 2, Share based payment. The estimated fair value of awards is charged to statement of profit or loss and other comprehensive income on a straight-line basis over the requisite vesting period for each separately vesting portion of the award as if the award was in-substance, multiple awards with a corresponding increase to share options outstanding account.

Equity-settled transactions

The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model.

That cost is recognised, together with a corresponding increase in share-based payment (SBP) reserves in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefits expense. The cumulative expense recognised for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company's best estimate of the number of equity instruments that will ultimately vest. The expense or credit for a period represents the movement in cumulative expense recognised as at the beginning and end of that period and is recognised in employee benefits expense.



2.16 CASH AND CASH EQUIVALENTS

Cash and cash equivalent in the statement of financial position comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less.

2.17 LEASES

The Company also elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option ('short-term leases'), and lease contracts for which the underlying asset is of low value ('low-value assets').

2.17.1 Right-of-use assets (ROU)

The Company recognises a right-of-use asset at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated under the straight-line method from the commencement date to the end of the lease term, unless the lease transfers ownership of the underlying asset to the Company by the end of the lease term or the cost of the right-of-use asset reflects that the Company will exercise a purchase option. In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The Company has included the right-of-use assets arising from the lease contracts within property, premise and equipment in the statement of financial position (Refer Note 7).

2.17.2 Lease liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate.

The variable lease payments that do not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. The Company determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and type of the asset leased. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset. The Company has included the lease obligations arising from the lease contracts within the other liabilities in the statement of financial position (Refer Note 11).

2.18 SEGMENT INFORMATION

2.18.1 Reportable Segment

The Company operates in only one business segment which is health insurance.

2.18.2 Geographical Segment

There are no reportable geographical segments since the Company provides services only to the customers in the Indian market and does not distinguish any reportable regions within India.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Notes to the financial statements

As at March 31, 2025

(Rs. in 000's)

3 CASH AND CASH EQUIVALENTS

Cash and bank balances

Total

As at
March 31, 2025

22,03,476

22,03,476

As at
March 31, 2024

14,28,168

14,28,168

4 INVESTMENTS

As at March 31, 2025

Quoted bonds

Mutual funds & Equity Shares*

Fixed Deposit

Less: Impairment loss allowance

Total

Amortised cost	Fair value through other comprehensive income	Fair value through profit or loss	Total Investments
-	7,83,76,511	-	7,83,76,511
-	-	29,72,278	29,72,278
13,50,000	-	-	13,50,000
-	(2,057)	-	(2,057)
13,50,000	7,83,74,454	29,72,278	8,26,96,732

As at March 31, 2024

Quoted bonds

Mutual funds & Equity Shares*

Fixed Deposit

Less: Impairment loss allowance

Total

-	5,22,78,927	-	5,22,78,927
-	-	11,60,871	11,60,871
9,98,000	-	-	9,98,000
-	(730)	-	(730)
9,98,000	5,22,78,197	11,60,871	5,44,37,068

Movement of Investments

Particulars	Amortised cost	Fair value through other comprehensive income	Fair value through profit or loss	Total Investments
	Fixed Deposit	Quoted bonds	Mutual funds & Equity Shares*	
From April 01, 2024 to March 31, 2025				
As at April 01, 2024	9,98,000	5,22,78,197	11,60,871	5,44,37,068
Purchase of investments	14,00,000	2,76,17,924	3,11,45,622	6,01,63,546
Sale of investments	(10,48,000)	(26,12,804)	(2,94,28,343)	(3,30,89,147)
Fair value gain/(loss)	-	10,92,464	(39,437)	10,53,027
Gain/(Loss) on sale of investments	-	-	1,33,565	1,33,565
Impairment gain/(loss) movement	-	(1,327)	-	(1,327)
As at March 31, 2025	13,50,000	7,83,74,454	29,72,278	8,26,96,732
From April 01, 2023 to March 31, 2024				
As at April 01, 2023	4,38,200	3,16,00,389	9,80,359	3,30,18,948
Purchase of investments	11,18,000	2,34,84,358	2,31,74,743	4,77,77,101
Sale of investments	(5,58,200)	(32,95,718)	(2,31,13,100)	(2,69,67,018)
Fair value gain/(loss)	-	4,96,963	39,210	5,36,173
Gain/(Loss) on sale of investments	-	(7,586)	79,659	72,073
Impairment gain/(loss) movement	-	(209)	-	(209)
As at March 31, 2024	9,98,000	5,22,78,197	11,60,871	5,44,37,068

*Mutual funds includes AIF and ETF. Equity shares includes InvIT.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the financial statements
As at March 31, 2025

5. RE-INSURANCE CONTRACTS ASSETS

Particulars	March 31, 2025				March 31, 2024				(Rs. in 000's)
	Assets for Remaining coverage		Reinsurance Commission	Assets for Incurred claims	Total	Assets for Remaining coverage	Reinsurance Commission	Assets for Incurred claims	Total
	Excluding loss - recovery component	Loss - recovery component							
Opening assets/ (liabilities)	52,00,743	-	(21,50,492)	27,24,465	57,74,716	38,70,080	(17,28,050)	18,84,220	40,26,250
Changes in the statement of Profit or Loss and OCI									
Net expenses from reinsurance contracts	(1,23,32,622)	(3,953)	45,08,030	71,99,996	(6,28,549)	(92,27,972)	34,34,110	53,10,575	(4,83,287)
Recoveries and reversals of recoveries of losses on onerous contracts	-	13,904	-	-	13,904	-	-	-	-
Cash Flow's									
Premiums paid	46,45,113	-	-	-	46,45,113	1,05,58,635	-	-	1,05,58,635
Amounts received	-	-	(13,58,647)	(44,87,290)	(58,45,937)	-	(38,56,552)	(44,70,330)	(83,26,882)
Closing assets/ (liabilities)	(24,86,766)	9,951	9,98,891	54,37,171	39,59,247	52,00,743	(21,50,492)	27,24,465	57,74,716

Note: Cohorts wise breakup is provided in Note 31.2



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the financial statements
As at March 31, 2025

6. INSURANCE CONTRACTS LIABILITIES

(Rs. in 000's)									
Particulars	March 31, 2025					March 31, 2024			
	Remaining coverage			Total	Incurred claims	Remaining coverage			Total
	Liability for Remaining coverage		Assets for Insurance Acquisition Cash flows			Liability for Remaining coverage	Assets for Insurance Acquisition Cash flows		
	Excluding loss component	Loss component							
Opening assets/ (liabilities)	(4,20,82,504)	-	1,39,28,420	(3,44,35,485)	(62,81,401)	(3,02,02,784)	97,28,647	(51,77,224)	(2,56,51,361)
Changes in statement of Profit or loss and OCI									
Insurance revenue									
Insurance revenue- contracts	5,83,99,082	-	-	5,83,99,082	-	4,41,78,659	-	-	4,41,78,659
Insurance service expenses									
Incurred claims and other insurance service expenses	-	98,827	-	(3,69,16,373)	(3,70,15,200)	-	-	(2,77,84,842)	(2,77,84,842)
Amortisation of insurance acquisition cash flows	-	-	(1,79,50,761)	(1,79,50,761)	-	-	(1,30,12,080)	-	(1,30,12,080)
Losses on onerous contracts and reversals of those contracts	-	(3,47,610)	-	(3,47,610)	-	-	-	-	-
Cash flows									
Premiums received	(7,41,06,885)	-	-	(7,41,06,885)	-	(5,60,58,379)	-	-	(5,60,58,379)
Claims and other insurance service expenses paid	-	-	-	3,49,33,140	3,49,33,140	-	-	2,66,80,665	2,66,80,665
Insurance acquisition cash flows	-	-	2,19,72,415	2,19,72,415	-	-	1,72,11,853	-	1,72,11,853
Closing assets/ (liabilities)	(5,77,90,307)	(2,48,783)	1,79,50,074	(4,84,52,477)	(83,63,461)	(4,20,82,504)	1,39,28,420	(62,81,401)	(3,44,35,485)

Note: Cohorts wise breakup is provided in Note 31.1



7 PROPERTY, PLANT AND EQUIPMENT

	Furniture	Computers	Office equipment	Leasehold improvements	Right-of-use assets	Capital work-in progress	Total
Cost							
As at April 01, 2024	74,215	4,42,903	1,66,119	1,96,140	9,66,021	5,072	18,50,470
Additions	23,777	84,816	17,502	98,131	3,75,454	4,18,595	10,18,275
Disposals	(615)	(459)	(9,865)	(2,015)	(1,05,000)	-	(1,17,954)
Transfer on Capitalization	-	-	-	-	-	(3,30,197)	(3,30,197)
As at March 31, 2025	97,377	5,27,260	1,73,756	2,92,256	12,36,475	93,470	24,20,594
Depreciation							
As at April 01, 2024	59,532	3,52,142	1,20,681	1,07,401	2,51,858	-	8,91,614
Depreciation for the year	9,929	58,549	21,330	23,238	1,57,572	-	2,70,618
Disposals	(565)	(408)	(9,358)	(1,233)	(37,954)	-	(49,518)
As at March 31, 2025	68,896	4,10,283	1,32,653	1,29,406	3,71,476	-	11,12,714
Net carrying amount							
As at March 31, 2025	28,481	1,16,977	41,103	1,62,850	8,64,999	93,470	13,07,880
Cost							
As at April 01, 2023	70,472	4,01,244	1,56,383	1,87,187	8,43,395	37,257	16,95,938
Additions	5,511	58,849	13,724	12,730	1,38,904	1,55,905	3,85,623
Disposals	(1,768)	(17,190)	(3,988)	(3,777)	(16,278)	-	(43,001)
Transfer on Capitalization	-	-	-	-	-	(1,88,090)	(1,88,090)
As at March 31, 2024	74,215	4,42,903	1,66,119	1,96,140	9,66,021	5,072	18,50,470
Depreciation							
As at April 01, 2023	52,559	3,18,089	1,02,201	91,655	1,20,683	-	6,85,187
Depreciation for the year	8,511	51,162	21,499	17,500	1,35,284	-	2,33,956
Disposals	(1,538)	(17,109)	(3,019)	(1,754)	(4,109)	-	(27,529)
As at March 31, 2024	59,532	3,52,142	1,20,681	1,07,401	2,51,858	-	8,91,614
Net carrying amount							
As at March 31, 2024	14,683	90,761	45,438	88,739	7,14,163	5,072	9,58,856



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Notes to the financial statements

As at March 31, 2025

(Rs. in 000's)

8 INTANGIBLE ASSETS

	Computer software	
	March 31, 2025	March 31, 2024
Cost as at April 01		
Opening	16,98,794	14,27,896
Additions (Refer note 2.11)	1,01,556	2,70,898
Disposals	(5,039)	-
Closing	17,95,311	16,98,794
Amortisation		
Opening	13,55,385	11,60,131
Amortisation for the year	1,33,098	1,95,254
Disposals	(2,799)	-
Closing	14,85,684	13,55,385
Net carrying amount	3,09,627	3,43,409

9 OTHER ASSETS

Accrued interest income	23,05,411	15,55,642
Prepaid expenses	3,63,198	1,44,741
Refundable deposits*	3,69,588	3,19,851
Tax credits	5,21,371	4,00,014
Others**	4,74,923	2,32,796
Total	40,34,491	26,53,044

* Includes Rs. 2,50,000 thousands (Previous year Rs. 2,50,000 thousands) paid to Directorate General of GST Intelligence (DGGI), Refer Note 18.

** Includes advance to suppliers & deposits against unclaimed amount of policyholders.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Notes to the financial statements

As at March 31, 2025

(Rs. in 000's)

10 BORROWINGS

At Amortised cost:

1500, 10.70% Subordinated, Redeemable, Non-Convertible Debentures of face value of Rs.10,00,000 each redeemable with interest on November 15, 2031

15,42,374

15,42,867

1000, 10.70% Subordinated, Redeemable, Non-Convertible Debentures of face value of Rs.10,00,000 each redeemable with interest on March 15, 2032

9,95,085

9,95,325

Total

25,37,459

25,38,192

Refer Note 32 for terms of borrowings

Reconciliation of movements of liabilities to cash flows arising from financing activities

Particulars	Equity			Liabilities	
	Share capital	Share application	Securities premium	Borrowings	Lease liabilities
As at April 01, 2024	1,69,95,346	1,915	1,29,10,127	25,38,192	8,01,952
Changes from financing cash flows					
Proceeds from issue of share capital	12,74,918	-	69,78,464	-	-
Transaction cost on issue of share capital	-	-	(2,99,243)	-	-
Proceeds from share application money	-	23,285	-	-	-
Interest on non-convertible debentures	-	-	-	(2,67,500)	-
Payment of lease liabilities	-	-	-	-	(2,09,110)
Total changes from financing cash flows	12,74,918	23,285	66,79,221	(2,67,500)	(2,09,110)
Other changes					
Liability-related					
New leases	-	-	-	-	3,75,454
Discontinued leases	-	-	-	-	(80,449)
Share based payment reserve	-	-	1,04,745	-	-
Interest expense	-	-	-	2,66,767	-
Interest paid	-	-	-	-	98,800
Total liability-related other changes	-	-	1,04,745	2,66,767	3,93,805
Total equity-related other changes	12,74,918	23,285	66,79,221	(2,67,500)	(2,09,110)
As at March 31, 2025	1,82,70,264	25,200	1,96,94,093	25,37,459	9,86,647

Particulars	Equity			Liabilities	
	Share capital	Share application	Share premium	Borrowings	Lease liabilities
As at April 01, 2023	1,51,06,779	-	33,71,223	25,34,786	7,69,477
Changes from financing cash flows					
Proceeds from issue of share capital	18,88,567	-	94,78,459	-	-
Proceeds from share application money	-	1,915	-	-	-
Interest on non-convertible debentures	-	-	-	(2,67,500)	-
Payment of lease liabilities	-	-	-	-	(1,73,828)
Total changes from financing cash flows	18,88,567	1,915	94,78,459	(2,67,500)	(1,73,828)
Other changes					
Liability-related					
New leases	-	-	-	-	1,38,904
Discontinued leases	-	-	-	-	(13,711)
Share based payment reserve	-	-	60,445	-	-
Interest expense	-	-	-	2,70,906	-
Interest paid	-	-	-	-	81,110
Total liability-related other changes	-	-	60,445	2,70,906	2,06,303
Total equity-related other changes	18,88,567	1,915	94,78,459	(2,67,500)	(1,73,828)
As at March 31, 2024	1,69,95,346	1,915	1,29,10,127	25,38,192	8,01,952



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED**Notes to the financial statements****As at March 31, 2025****(Rs. in 000's)****11 OTHER LIABILITIES**

	As at March 31, 2025	As at March 31, 2024
Accounts payable	41,25,042	36,64,921
Lease liabilities	9,86,647	8,01,952
Salaries and employee benefit liabilities*	5,88,738	5,63,456
Statutory dues payable	21,25,142	10,88,665
Premium received in advance	22,55,892	10,12,599
Others	12,228	13,298
Total	1,00,93,689	71,44,891

* Includes provision for defined benefit plans



12 SHARE CAPITAL

i) Authorised share capital

Equity share capital of Rs. 10 each

Particulars	Number of shares	Amount
As at April 01, 2023	5,00,00,00,000	5,00,00,000
Increase during the year	-	-
As at March 31, 2024	5,00,00,00,000	5,00,00,000
Increase during the year	-	-
As at March 31, 2025	5,00,00,00,000	5,00,00,000

ii) Issued share capital

Equity share capital of Rs. 10 each

Particulars	Number of shares	Amount
As at April 01, 2023	1,51,06,77,916	1,51,06,779
Increase during the year	18,88,56,679	18,88,567
As at March 31, 2024	1,69,95,34,595	1,69,95,346
Increase during the year*	12,74,91,803	12,74,918
As at March 31, 2025	1,82,70,26,398	1,82,70,264

* Increase in share capital during the year is on account of issue of 10,81,08,108 shares during IPO and 1,93,83,695 shares due to exercise of ESOP.

(iii) Terms/ rights attached to equity shares

The Company has a single class of equity share of par value Rs. 10 each. Each holder of the equity shares is entitled to one vote per share and carries a right to dividends as and when declared by the Company. In the event of liquidation of the Company, the holders of equity shares, will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED

Notes to the financial statements

As at March 31, 2025

(Rs. in 000's)

12(a) OTHER EQUITY

Particulars	As at March 31, 2025	As at March 31, 2024
Retained earnings	(60,41,385)	(80,64,364)
Securities premium	1,96,94,093	1,29,10,127
Fair value reserve	7,15,841	(1,01,672)
Share based payments reserve	2,59,717	2,33,803
Share application pending for allotment	25,200	1,915
Total	1,46,53,466	49,79,809

Retained earnings

Retained earnings comprises of the Company's undistributed earnings after taxes.

Securities premium

Securities premium reserve is used to record the premium on issue of shares. The reserve can be utilised only for limited purposes in accordance with the provisions of the Companies Act, 2013.

Fair value reserve

The Company measures its financial instruments i.e. debt instruments at fair value at each reporting date. Fair value is the price that would be received in an orderly transaction to sell an asset between market participants at the measurement date under current market conditions.

Share based payments reserve

The share based payments reserve represents the reserve in respect of equity settled share options granted to the employees of the Company.

Share application pending for allotment

Share application money pending for allotment represents the amount received on exercise of ESOP application on which allotment is not yet made.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the financial statements
For the year ended March 31, 2025
(Rs. in 000's)
13 OTHER OPERATING EXPENSES

	For the year ended March 31, 2025	For the year ended March 31, 2024
Employee benefit expenses	22,32,713	21,79,608
Business promotion, travel and entertainment	14,35,341	13,13,006
Legal & professional fees	1,02,309	73,502
Remuneration to Auditors (refer note below)	13,332	6,658
Training expenses	59,852	2,31,335
Office operation	2,66,540	1,03,186
Depreciation and amortization	2,06,930	2,82,247
Board of directors' expenses	16,937	17,329
Others	13,235	28,424
Total	43,47,189	42,35,295

Remuneration to Auditors

- Statutory audit fees	11,800	4,900
- Other services including certification work	1,014	1,289
- Reimbursement of expenses	518	469
Total	13,332	6,658

14 FINANCE COST

Interest on subordinated debentures	2,66,767	2,70,906
Interest expense for lease liabilities (Refer Note 19)	98,800	81,110
Total	3,65,567	3,52,016

15 INVESTMENT INCOME

Interest income on financial assets carried at fair value through other comprehensive income	45,17,765	29,01,290
Interest income on financial assets carried at amortized cost	70,307	37,896
Net gain on sale of investments	1,33,565	72,074
Interest and dividend income on financial assets carried at fair value through profit and loss	76,640	30,967
Net fair value (losses)/gains on financial assets at fair value through profit or loss	(39,437)	39,210
Total	47,58,840	30,81,437



	(Rs. in 000's)	
16 (a) INCOME TAXES	For the year ended March 31, 2025	For the year ended March 31, 2024
Current tax	-	-
Deferred tax:		
Origination and reversal of temporary differences	10,02,558	4,89,156
Recognised in statement of profit or loss	7,31,191	3,65,749
Recognised in statement of other comprehensive income	2,71,367	1,23,407
Total	10,02,558	4,89,156
Income tax charge for the year	10,02,558	4,89,156
(b) DEFERRED TAX BALANCES	As at March 31, 2025	As at March 31, 2024
The deferred tax balances comprises:		
Deferred tax asset:		
Investments	-	34,358
Security deposits	982	901
Leases	30,616	22,095
Employee stock option plan	65,031	58,013
Property, plant and equipments & Intangible assets	39,386	46,375
Brought forward loss*	77,106	2,05,923
Unabsorbed depreciation*	-	4,15,884
	2,13,121	7,83,549
Deferred tax liability:		
Investments	(2,30,334)	-
Insurance contract liabilities	(4,79,897)	(2,78,283)
Borrowings	(6,988)	(6,804)
	(7,17,219)	(2,85,087)
Deferred tax asset/(liability)	(5,04,098)	4,98,462

The Government of India on December 12, 2019 vide the Taxation Laws (Amendment) Act 2019 inserted a new section 115BAA in the Income Tax Act 1961, which provides an option to the company for paying Income Tax at reduced rates as per provisions/conditions defined in said section. The company has exercised the said option and therefore has disclosed the deferred tax assets/(liability) as above,

* Deferred tax asset has been recognised for unused tax losses and unabsorbed depreciation (i.e. deductible temporary differences) as per the Income Tax Act, 1961, since it is probable that taxable profits will be available against which the deductible temporary differences can be utilised. The management believes due to recent business performance, developments and budgets, revised its estimates of future taxable profits and therefore, management continues to consider it probable that future taxable profits would be available against which the tax losses can be recovered and, therefore, the related deferred tax asset can be realised.

	(Rs. in 000's)	
(c) RECONCILIATION OF TAX EXPENSE AND TAX BASED ON ACCOUNTING PROFIT:	For the year ended March 31, 2025	For the year ended March 31, 2024
Accounting Profit/(Loss) before income tax expense	27,60,226	14,29,295
Tax at the Indian tax rate of 25.17%	(6,94,749)	(3,59,754)
Others	(36,442)	(5,995)
Income tax expenses reported in the statement of profit or loss	(7,31,191)	(3,65,749)



17. EARNING PER SHARE (EPS)

Profit available to equity holders (for Basic EPS)

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Profit available to equity holders	20,29,035	10,63,546
Profit available to equity holders of the Company (A)	20,29,035	10,63,546

Weighted average number of equity shares

Particulars	(Count in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Issued equity shares at the beginning of the year	16,99,534	15,10,678
Effect of issue of equity shares and exercise of share options	53,362	79,610
Weighted average number of equity shares at the end of the year for basic EPS (B)	17,52,896	15,90,288
Effect of dilution:		
Potential equity shares*	28,957	41,127
Weighted average number of equity shares at the end of the year for diluted EPS (C)	17,81,853	16,31,415

* Dilutive impact of Employee Stock Option.

Basic and Diluted earnings per share

Particulars	(in Rs.)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Basic earnings per share (A/B)	1.16	0.67
Diluted earnings per share (A/C)	1.14	0.65

18. PROVISIONS, CONTINGENT LIABILITY AND COMMITMENTS

Particulars	(Rs. in 000's)		
	Statutory Demands in Dispute, not provided for	Others- Claims, under policies, not acknowledged as debts*	Total
As at March 31, 2023	1,20,172	3,47,382	4,67,554
Addition	3,27,473	2,08,143	5,35,616
Used (Amount charged against the provision)	-	(3,853)	(3,853)
Used Amount Reversed	-	(7,979)	(7,979)
As at March 31, 2024	4,47,645 [#]	5,43,693	9,91,338
Addition	10,33,674	2,91,015	13,24,689
Used (Amount charged against the provision)	(28,762)	(51,287)	(80,049)
Used Amount Reversed	(1,97,443)	(93,610)	(2,91,053)
As at March 31, 2025	12,55,114	6,89,811	19,44,925

* Includes compensation raised by policyholders against rejected claims. It does not include interest on compensation to be awarded by the court if any.

[#] Refer Note 3 & 4 below.

Notes: -

(1) The Company has disputed the demand raised by Income Tax Authorities of Rs. 9,87,904 thousands (previous year: Nil) the appeals of which are pending before the appropriate authorities. This includes income tax demand related to Assessment Year 2020-21, 2021-22 and 2022-23. The Company does not expect the outcome of these proceedings to have a material adverse effect on its financial statements as at March 31, 2025.



(2) Pursuant to an inquiry by Directorate General of GST Intelligence (DGGI) relating to certain input credit availed by the Company, it has provided all information and clarifications to DGGI. As directed by DGGI authorities, the Company has paid Rs. 2,50,000 thousands under Section 74(5) of the CGST Act 2017 which includes GST refund of Rs. 2,21,238 thousands (previous year Rs. Nil) rejected by Goods & Services Tax authorities against which the Company is in process of evaluating necessary legal recourse. The Company has shown this amount in Contingent Liability.

The Company has received order from GST Authorities and reduced demand from Rs. 2,92,879 thousands to Rs. 28,762 thousands. The Company has decided not to appeal against the same and paid the said amount along with interest and penalty. The Company has debited Rs. 52,454 thousands to profit and loss A/c.

(3) The Company has disputed the demand raised by Income Tax Authorities of Rs. 1,15,809 thousands the appeals of which are pending before the appropriate authorities. This includes income tax demand related to Assessment Year 2013-14, 2014-15 and 2016-17 in respect of which the Company has received the favorable appellate order, which is pending for effect to be given by Assessing Authority. The Company does not expect the outcome of these proceedings to have a material adverse effect on its financial statements as at March 31, 2024.

(4) Includes demand of Rs. 3,31,836 thousands from Goods & Services Tax authorities, for which show cause/demand notice has been issued by the department and the Company has filed the reply accordingly.

Pending Litigations

The Company's pending litigations comprise of claims against the Company primarily by customers and proceedings pending with Tax authorities. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed the contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a material adverse effect on its financial statements as at March 31, 2025.

Capital Commitments

Estimated amount of commitments pertaining to contracts remaining to be executed in respect of fixed assets (net of advances) is Rs. 2,72,326 thousands (previous year Rs. 47,924 thousands).

Other Commitments

Commitment in respect of loans as on March 31, 2025 is Rs. Nil (previous year: Nil) and Investment is Rs. Nil (previous year: Nil).

19. LEASES

Movement of ROU Asset

	<i>(Rs. in 000's)</i>	
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Balance as at beginning of the year	7,14,163	7,22,712
Add: Addition during the year	3,75,454	1,38,904
Less: Depreciation	(1,57,572)	(1,35,284)
Less: Disposal during the year	(67,046)	(12,169)
Closing balance at the end of the year	8,64,999	7,14,163

Movement of Lease Liability

	<i>(Rs. in 000's)</i>	
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Balance as at beginning of the year	8,01,952	7,69,477
Add: Addition during the year	3,75,454	1,38,904
Add: Accretion of interest	98,800	81,110
Less: Payments during the year	(2,09,110)	(1,73,828)
Less: Disposal during the year	(80,449)	(13,711)
Closing balance at the end of the year	9,86,647	8,01,952



Other disclosures

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Incremental Borrowing Rate of Company	10.70%	10.70%
The leases have a life of between	1 to 9 years	1 to 9 years
The total lease payments for the year (Rs.000)	2,09,110	1,73,828

20. EMPLOYEE BENEFITS

20.1 Gratuity - Defined benefit plans

In accordance with International Accounting Standard 19 (IAS 19) on Employee Benefits, the information is set out below:

Table 1: Change in Defined Benefit Obligation during the Year

(Rs. in 000's)		
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Defined Benefit Obligation, Beginning of Year	1,46,515	1,06,767
Total Service Cost	40,287	32,153
a. Current Service Cost	40,287	32,153
Interest on Defined Benefit Obligation	9,918	7,193
Total Cashflows	(7,610)	(10,927)
a. Actual Benefits Paid	(7,610)	(10,927)
Remeasurements due to:		
a. Effect of Change in financial assumptions	5,104	952
b. Effect of Change in demographic assumptions	(5,709)	-
b. Effect of experience adjustments	18,813	10,377
Defined Benefit Obligation, End of Year	2,07,318	1,46,515

Table 2: Change in Fair value of Plan Assets during the Year

(Rs. in 000's)		
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Fair value of Plan Assets, Beginning of Year	1,06,609	80,284
Interest Income	10,525	6,246
Total Cashflows	89,661	15,369
a. Actual Employer Contributions	97,271	26,296
b. Actual Benefits Paid	(7,610)	(10,927)
Remeasurements		
a. Return on plan assets (excluding interest)	3,970	4,710
Fair value of Plan Assets, End of Year	2,10,765	1,06,609

Table 3: Net Defined Benefit Liability / (Asset)

(Rs. in 000's)		
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Defined Benefit Obligation	2,07,318	1,46,514
Fair value of plan Assets	2,10,765	1,06,609
Funded Status - (Surplus)/Deficit	(3,447)	39,905
Net Defined Benefit Liability / (Asset) Recognized in Statement of Financial Position	(3,447)	39,905



Table 4: Total Net Defined Benefit Cost/(Income) included in Profit & Loss

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Total Service Cost	40,287	32,153
Current Service Cost	40,287	32,153
Net Interest Cost (Income)	(607)	947
a. Interest expense on DBO	9,918	7,193
b. Interest Income on Plan Assets	(10,525)	(6,256)
Net Defined Benefit Cost/(Income) included in P&L	39,680	33,090

Table 5: Actual Return on Plan Assets

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest Income Plan Asset	10,525	6,256
Remeasurements on Plan Assets	3,970	4,700
Actual Return on Plan Assets	14,495	10,956

Table 6: Remeasurements recognized in Other Comprehensive Income (OCI) outside Profit & Loss account

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Amount recognized in OCI, Beginning of Year	10,973	4,344
Remeasurements due to:		
a. Effect of Change in financial assumptions	5,104	952
b. Effect of Change in demographic assumptions	(5,709)	-
b. Effect of experience adjustments	18,813	10,377
c. Return on Plan Assets (excluding interest)	(3,970)	(4,700)
Total remeasurements recognized in OCI	14,238	6,629
Amount recognized in OCI, End of Year	25,211	10,973

Table 7: Net Defined Benefit Cost Recognized in Profit & Loss and OCI

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Amount recognized in P&L, End of Year	39,680	33,090
Amount recognized in OCI, End of Year	14,238	6,629
Total Net Defined Benefit Cost	53,918	39,719

Table 8: Current / Non-Current Benefit Obligation

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Current Liability/ (Asset)	-	-
Non-Current Liability/ (Asset)	(3,447)	39,905
Net Defined Benefit Liability / (Asset) Recognized in Statement of Financial Position	(3,447)	39,905




Table 9: Category of Assets

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Schemes of insurance	100%	100%

Table 10: Defined benefit obligation by participant status & Experience (Gain)/Loss

(Rs. in 000's)		
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
a. Actives	2,07,317	1,46,514
b. Vested Deferred	-	-
c. Retirees	-	-
Total	2,07,317	1,46,514
Experience (gain)/ loss on plan liabilities		
a. Amount	18,813	10,377
b. Percentage of present value of plan liabilities	9.07%	7.08%

Sensitivity Analysis

The key assumptions which are sensitive to the defined benefit obligation are the discount rate and the salary escalation rate. The below table summarizes the impact of these assumptions on the DBO when increase or decrease by 50 basis points.

(Rs. in 000's)		
Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
DBO @ Discount Rate + 0.5%	2,03,046	1,43,386
DBO @ Discount Rate - 0.5%	2,11,769	1,49,774
DBO @ Salary Escalation Rate + 0.5%	2,11,679	1,49,727
DBO @ Salary Escalation Rate - 0.5%	2,03,091	1,43,402

Actuarial Assumptions

Financial Assumptions	For the year ended March 31, 2025	For the year ended March 31, 2024
Discount Rate	6.35%	6.95%
Salary Escalation Rate	8.00%	8.00%
Expected Return on Assets	6.35%	6.95%

Demographic Assumptions	For the year ended March 31, 2025	For the year ended March 31, 2024
Withdrawal Rate	50% for Front Line Sales Staff and 20% for Other Staff	40% for Front Line Sales Staff and 20% for Other Staff
Mortality Table *	Indian Assured Lives Mortality (2012-14) Ult.	Indian Assured Lives Mortality (2012-14) Ult.
Retirement Age	58 years	58 years

Timing Related Assumptions	
Time of Retirement	Immediately on achieving normal retirement
Salary Increase frequency	Once a year



* Mortality Rates: Representative mortality rates from Indian Assured Lives Mortality 2012-14 are given in the table below.

Age	Rate	Age	Rate
20	0.0009240	50	0.0044360
25	0.0009310	55	0.0075130
30	0.0009770	60	0.0111620
35	0.0012020		
40	0.0016800		
45	0.0025790		

20.2 Defined contribution plans

During the year the Company has recognized the following amounts in the statement of profit or loss:

Particulars	(Rs. in 000's)	
	For the year ended March 31, 2025	For the year ended March 31, 2024
Employer's contribution to provident fund and state insurance	2,20,851	2,41,197

20.3 Share based payment

In accordance with IFRS 2 Share-based Payments, the information is set out below:

The Company had introduced "Employee Stock Option Plan - 2020 (ESOP 2020)" in the financial year 2020-21 effective from June 01, 2020 (date of grant) and "Employee Stock Option Plan - 2024 (ESOP 2024)" in the financial year 2023-24 effective from December 13, 2023. Under the ESOP Scheme 2020 and 2024 the Company has given options to eligible Employees to acquire equity shares in the Company. The options have been granted under various tranches.

20.3.1 ESOP Scheme 2020

Scheme	Date of grant	Numbers granted	Exercise period from the date of grant of the Options (in years)	Vesting conditions	Exercise price per option	Estimated fair value* of share granted
Series-1 (A)	01-Jun-20	2,78,00,000	10	10.72% at 1 st anniversary from date of Grant 17.32% at 2 nd anniversary from date of Grant 17.32% at 3 rd anniversary from date of Grant 17.32% at 4 th anniversary from date of Grant 37.32% at 5 th anniversary from date of Grant	10.00	4.24
Series-1 (B)	01-Jun-20	3,48,00,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.24
Series-2	01-Sep-20	77,50,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.18
Series-3	05-Sep-20	2,50,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.18
Series-4	06-Oct-20	2,50,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.18



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

Series-5	10-Oct-20	4,00,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.18
Series-6	02-Nov-20	10,00,000	10	13.40% at 1 st anniversary from date of Grant 21.65% at 2 nd anniversary from date of Grant 21.65% at 1 st June 2023 21.65% at 1 st June 2024 21.65% at 1 st June 2025	10.00	4.18
Series-7	23-Feb-21	29,50,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 1 st June 2023 20% at 1 st June 2024 20% at 1 st June 2025	10.00	6.51
Series-8	01-Apr-21	2,00,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 1 st June 2023 20% at 1 st June 2024 20% at 1 st June 2025	10.00	3.10
Series-9	11-Jun-21	14,50,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	12.66	2.40
Series-10	13-Oct-21	68,15,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	23.46	9.92
Series-11	25-Oct-21	1,25,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	23.46	9.92
Series-12	01-Nov-21	12,50,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	23.46	9.92
Series-13	01-Jun-22	26,24,500	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	31.92	12.92
Series-14	23-Jan-23	24,67,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	33.25	13.41
Series-15	25-Apr-23	2,60,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	33.25	13.41
Series-16	10-Aug-23	3,50,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	53.09	21.19
Series-17	03-Oct-23	18,50,000	10	20% at 1 st anniversary from date of grant 20% at 2 nd anniversary from date of grant 20% at 3 rd anniversary from date of grant 20% at 4 th anniversary from date of grant 20% at 5 th anniversary from date of grant	67.15	26.54



ESOP Scheme 2024

Scheme	Date of grant	Numbers granted	Exercise period from the date of grant of the Options (in years)	Vesting conditions	Exercise price per option	Estimated fair value* of share granted
Series-18	01-Apr-24	36,31,562	10	0% at 1 st anniversary from date of grant 50% at 2 nd anniversary from date of grant 25% at 3 rd anniversary from date of grant 25% at 4 th anniversary from date of grant	67.19	25.11
Series-19	27-May-24	49,47,000	10	0% at 1 st anniversary from date of grant 50% at 2 nd anniversary from date of grant 25% at 3 rd anniversary from date of grant 25% at 4 th anniversary from date of grant	67.19	25.11
Series-20	14-Aug-24	82,500	10	0% at 1 st anniversary from date of grant 50% at 2 nd anniversary from date of grant 25% at 3 rd anniversary from date of grant 25% at 4 th anniversary from date of grant	67.19	25.11


* The fair value of the options granted has been calculated as per the Black-Scholes option pricing model. It also details the variables used for the calculation of fair value along-with the rationale behind them.

20.3.2 Movement during the year

The following table provides the details of ESOP schemes in terms of options forfeited, options exercised, options outstanding and options exercisable:

For the year ended March 31, 2025

Scheme	Outstanding at the Beginning of the year	Granted During the year	Cancellation of Options due to Resignation/Sur render during the year	Exercised During the year	Outstanding at the end of the year	Exercisable as at March 31, 2025	Remaining contractual life (in years)
Series - 1 (A)	1,82,04,880	-	-	78,29,920	1,03,74,960	-	5.17
Series - 1 (B)	1,31,80,490	-	-	69,45,290	62,35,200	-	5.17
Series - 2	11,13,225	-	-	4,92,900	6,20,325	1,11,550	5.42
Series - 3	1,08,250	-	-	54,125	54,125	-	5.44
Series - 4	1,62,500	-	-	1,08,000	54,500	375	5.52
Series - 5	1,99,800	-	-	86,600	1,13,200	26,600	5.53
Series - 6	4,33,000	-	-	2,16,500	2,16,500	-	5.59
Series - 7	13,69,000	-	50,000	8,03,387	5,15,613	45,613	5.90
Series - 8	80,000	-	40,000	40,000	-	-	6.01
Series - 9	9,29,921	-	-	3,49,921	5,80,000	-	6.20
Series - 10	45,54,000	-	3,40,000	12,63,000	29,51,000	9,86,000	6.54
Series - 11	75,000	-	-	-	75,000	25,000	6.57
Series - 12	7,50,000	-	5,00,000	-	2,50,000	2,50,000	6.59
Series - 13	22,34,000	-	2,47,500	5,05,000	14,81,500	14,000	7.18
Series - 14	22,79,000	-	90,000	2,79,000	19,10,000	4,70,000	7.82
Series - 15	2,60,000	-	-	25,000	2,35,000	19,000	8.07
Series - 16	3,50,000	-	-	55,000	2,95,000	15,000	8.37
Series - 17	18,50,000	-	-	3,30,052	15,19,948	39,948	8.52
Series - 18	-	36,31,562	-	-	36,31,562	-	9.00
Series - 19	-	49,47,000	1,80,500	-	47,66,500	-	9.16
Series - 20	-	82,500	-	-	82,500	-	9.37



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

For the year ended March 31, 2024

Scheme	Outstanding at the Beginning of the year	Granted During the year	Cancellation of Options due to Resignation/Surrender during the year	Exercised During the year	Outstanding at the end of the year	Exercisable as at March 31, 2024	Remaining contractual life (in years)
Series -1 (A)	2,41,04,880	-	-	59,00,000	1,82,04,880	30,14,960	6.17
Series -1 (B)	1,89,56,740	-	-	57,76,250	1,31,80,490	7,10,090	6.17
Series -2	15,34,625	-	-	4,21,400	11,13,225	95,675	6.42
Series -3	1,62,375	-	-	54,125	1,08,250	-	6.44
Series -4	2,16,500	-	-	54,000	1,62,500	54,250	6.52
Series -5	2,59,800	-	-	60,000	1,99,800	26,600	6.53
Series -6	6,49,500	-	-	2,16,500	4,33,000	-	6.59
Series -7	19,20,000	-	1,20,000	4,31,000	13,69,000	4,29,000	6.90
Series -8	2,00,000	-	-	1,20,000	80,000	-	7.01
Series -9	11,60,000	-	-	2,30,079	9,29,921	59,921	7.20
Series -10	54,02,000	-	5,56,000	2,92,000	45,54,000	5,78,000	7.54
Series -11	1,00,000	-	-	25,000	75,000	-	7.57
Series -12	10,00,000	-	-	2,50,000	7,50,000	-	7.59
Series -13	25,45,500	-	1,62,500	1,49,000	22,34,000	1,95,000	8.18
Series -14	24,67,000	-	1,20,000	68,000	22,79,000	3,54,000	8.82
Series -15	-	2,60,000	-	-	2,60,000	-	9.07
Series -16	-	3,50,000	-	-	3,50,000	-	9.37
Series -17	-	18,50,000	-	-	18,50,000	-	9.52

The weighted average remaining contractual life for the share options outstanding as at March 31, 2025 is 6.67 years (Previous year 6.77 years).

The range of exercise prices for options outstanding at the end of the year was Rs. 10.00 to Rs. 67.19 (Previous year Rs. 10.00 to Rs. 67.15).

The weighted average fair value of options granted during the year was Rs. 25.11 (Previous year Rs. 24.41).



20.3.3 Actuarial Assumptions:

Schemes	Exercise price (Rs.)	Expected life of the options (in years)	Expected volatility (% p.a.)	Risk free discount rate (% p.a.)	Expected dividend yield (% p.a.)
Series -1	9.79	3.50-7.51	37.36	5.05-6.05	-
Series -2	9.79	3.50-7.51	36.49	5.03-6.05	-
Series -3	9.79	3.50-7.51	36.49	5.03-6.05	-
Series -4	9.79	3.50-7.51	36.49	5.03-6.05	-
Series -5	9.79	3.50-7.51	36.49	5.03-6.05	-
Series -6	9.79	3.50-7.51	36.49	5.03-6.05	-
Series -7	12.66	3.50-7.51	35.48	5.22-6.29	-
Series -8	8.40	3.50-7.51	35.25-35.31	5.26-6.38	-
Series -9	8.40	3.50-7.51	34.9-35.6	5.13-6.23	-
Series -10	23.46	3.50-7.51	34.12-35.00	5.14-6.32	-
Series -11	23.46	3.50-7.51	34.12-35.00	5.14-6.32	-
Series -12	23.46	3.50-7.51	34.12-35.00	5.14-6.32	-
Series -13	31.92	3.51-7.51	26.25-28.39	6.82-7.38	-
Series -14	33.25	3.51-7.51	25.46-27.89	7.06-7.28	-
Series -15	33.25	3.51-7.51	25.46-27.89	7.06-7.28	-
Series -16	53.09	3.51-7.51	25.29-29.44	7.00-7.06	-
Series -17	67.15	3.51-7.51	24.98-24.85	7.12-7.16	-
Series -18	67.19	4.00-6.00	26.82-29.87	6.96-6.97	-
Series -19	67.19	4.00-6.00	26.82-29.87	6.96-6.97	-
Series -20	67.19	4.00-6.00	26.82-29.87	6.96-6.97	-

21. RELATED PARTIES & TRANSACTIONS:

As per the International Accounting Standard-24 (IAS-24) on 'Related Party Disclosures', the related parties of the Company are as follows:

SN	Description of Relationship	Name of Party
(a)	Ultimate Holding Company	British United Provident Association Limited (w.e.f. 04th January 2024) True North Fund VI LLP (till 03rd January 2024)
(b)	Intermediate Holding Company	Bupa Finance plc (w.e.f. 04th January 2024) Bupa Investments Overseas Limited (w.e.f. 04th January 2024)
(c)	Holding Company	Bupa Singapore Holdings Pte Ltd (w.e.f. 04th January 2024) Fettle Tone LLP (till 03rd January 2024)
(d)	Significant Influence	Fettle Tone LLP (till 11 th November 2024) Bupa Singapore Holdings Pte Ltd (till 03rd January 2024)
(e)	Key Management Personnel (KMP)	Mr. Krishnan Ramachandran, Managing Director and Chief Executive Officer Mr. Vishwanath Mahendra, Chief Financial Officer Mr. Rajat Sharma, Company Secretary
(f)	Post-employment benefit plan of Niva Bupa Health Insurance Company Limited	Max Bupa Health Insurance Limited Employees Group Gratuity Fund



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

Details of transaction with related parties for the year ended March 31, 2025 and March 31, 2024 are given below:
(Rs. in 000's)

SN	Transactions	Name of the Related Party	Description	For the year ended March 31, 2025	For the year ended March 31, 2024
1	Issuance of Share capital	Fettle Tone LLP	Significant Influence	-	2,22,276
2	Issuance of Share capital	Bupa Singapore Holdings Pte Ltd	Holding Company	-	3,31,037
3	Share premium received	Fettle Tone LLP	Significant Influence	-	9,81,904
4	Share premium received	Bupa Singapore Holdings Pte Ltd	Holding Company	-	16,56,863
5	Issuance of Share Capital	Mr. Krishnan Ramachandran MD & CEO	Key Management Personnel	-	1,327
6	Issuance of Share Capital	Mr. Vishwanath Mahendra, CFO	Key Management Personnel	-	5,849
7	Issuance of Share Capital	Mr. Rajat Sharma, Company Secretary	Key Management Personnel	333	-
8	ESOP Exercised	Mr. Krishnan Ramachandran MD & CEO	Key Management Personnel	78,299	59,000
9	ESOP Exercised	Mr. Vishwanath Mahendra, CFO	Key Management Personnel	8,660	8,660
10	Recovery of IPO Expenses	Bupa Singapore Holdings Pte Ltd	Holding Company	1,28,093	-
11	Employee's Remuneration	Mr. Krishnan Ramachandran, MD & CEO	Key Management Personnel	50,236	51,829
12	Employee's Remuneration	Mr. Vishwanath Mahendra, CFO	Key Management Personnel	23,787	23,232
13	Employee's Remuneration	Mr. Rajat Sharma, CS	Key Management Personnel	4,867	3,549
14	Benefits Received	Max Bupa Health Insurance Limited Employees Group Gratuity Fund	Post-employment benefit plan of Niva Bupa Health Insurance Company Limited	7,488	10,927
15	Contribution Paid	Max Bupa Health Insurance Limited Employees Group Gratuity Fund	Post-employment benefit plan of Niva Bupa Health Insurance Company Limited	97,148	26,296

Note:

1. The Company has completed Initial Public Offer (IPO) of equity shares of face value Rs.10 each at an issue price of Rs.74 per equity share, comprising of fresh issue of 10,81,08,108 shares and offer for sale of 18,91,89,188 shares by 'selling share holders'.

2. Provision towards gratuity and leave encashment are determined actuarially on an overall Company basis annually and accordingly have not been considered for the above disclosure. Perquisites are calculated as per Income Tax Rules, 1962 and above figures does not include perquisites.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

Details of Shares with related parties are as given below:

SN	Outstanding Balances	Name of the Related Party	Description	As at March 31, 2025 (Rs. in 000's)	Number of shares as at March 31, 2025	As at March 31, 2024 (Rs. in 000's)	Number of shares as at March 31, 2024
1	Equity Share Capital	Bupa Singapore Holdings Pte Ltd	Holding Company	10,22,690	1,02,26,90,470	1,06,99,878	1,06,99,87,767
2	Equity Share Capital	Fettle Tone LLP	Significant Influence	3,19,129	31,91,28,920	47,86,679	47,86,67,869
3	Equity Share Capital	Key Management Personnel (KMP)	ESOP and Right Shares	14,104	1,41,04,210	1,04,083	1,04,08,290

22. CAPITAL WORK-IN PROGRESS (CWIP)

Ageing for CWIP is as follows:

Ageing for EWR is as follows:

(Rs. in 000's)

Particulars	Ageing		Total
	Less than 1 year		
As at March 31, 2025		93,470	93,470
As at March 31, 2024		5,072	5,072

22.2 During the year ended March 31, 2024, the Company had reassessed the useful lives of certain business applications. The management believes that the revised useful lives of the assets reflect the period over which these assets are expected to be used based on the technical inputs and capability analysis. As a result of change, the charge in the statement of profit or loss on account of depreciation for the year ended March 31, 2024, has decreased by Rs. 1,97,687 thousands.

23. CAPITAL

Available capital resources:

Particulars	As at	
	March 31, 2025	March 31, 2024
Total equity	3,29,23,730	2,19,75,155
Available capital resources	3,25,13,402	2,25,68,600
Prescribed capital amount	1,61,08,277	1,32,62,850

The adjustments onto a regulatory basis represent assets inadmissible for regulatory reporting purposes.



24. FINANCIAL INSTRUMENTS

24.1 Fair value of financial instruments

The following tables provide the fair value measurement hierarchy of the Company's assets and liabilities.

Fair value measurement hierarchy for assets as at March 31, 2025

(Rs. in 000's)

Particulars	Date of valuation*	Total	Fair value measurement using		
			Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets measured at fair value (Refer Note 4):					
a. Mutual funds & Equity Shares**	March 28, 2025	29,72,278	29,22,278	-	50,000
b. Quoted bonds	March 28, 2025	7,83,76,511	-	7,83,76,511	-

Fair value measurement hierarchy for assets as at March 31, 2024

(Rs. in 000's)

Particulars	Date of valuation*	Total	Fair value measurement using		
			Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets measured at fair value (Refer Note 4):					
a. Mutual funds & Equity Shares**	March 29, 2024	11,60,871	11,60,871	-	-
b. Quoted bonds	March 29, 2024	5,22,78,927	-	5,22,78,927	-

* The last market active date before the end of the year is used in the fair valuation.

** Mutual funds includes AIF and ETF. Equity shares includes InvIT.

There are no other financial assets of the Company measured at fair value.

There are no financial liabilities of the Company measured at fair value.

There have been no transfers or movements in any levels during the year ended March 31, 2025 and March 31, 2024.

Total gains or losses for the year recognised in profit or loss are presented in Note 15 and unrealised gains and losses of them are presented in Note 15 in the statement of profit or loss.

Total gains or losses for the year recognised in OCI are presented in 'Net fair value gains/(losses) on financial assets at fair value through other comprehensive income' in the statement of Other Comprehensive Income.



24.2 Credit exposure

The table below provides information regarding the credit risk exposure of the Company's investments by classifying into various sub sectors.

Industry Analysis

(Rs. in 000's)

As at March 31, 2025	Fixed Deposits at Amortised Cost	Mutual funds & Equity Shares at FVTPL*	Quoted bonds at FVTOCI	Total credit risk exposure
Financial and Insurance Activities	13,50,000	6,63,606	1,60,82,031	1,80,95,637
Sovereign	-	-	2,39,65,056	2,39,65,056
Civil engineering	-	-	10,71,872	10,71,872
Manufacture of coke and refined petroleum products	-	-	7,48,076	7,48,076
Manufacture of other non-metallic mineral products	-	-	3,58,279	3,58,279
Manufacture of basic metals	-	-	10,56,498	10,56,498
Electric power generation, transmission & distribution	-	68,543	55,00,873	55,69,416
Housing	-	-	93,63,294	93,63,294
Real estate activities on a fee or contract basis	-	-	7,48,100	7,48,100
Liquid mutual fund	-	22,20,129	-	22,20,129
Infrastructure	-	20,000	1,81,29,195	1,81,49,195
Wholesale of food, beverages and tobacco	-	-	13,51,180	13,51,180
Manufacture of chemicals and chemical products	-	-	-	-
Total	13,50,000	29,72,278	7,83,74,454	8,26,96,732

(Rs. in 000's)

As at March 31, 2024	Fixed Deposits at Amortised Cost	Mutual funds & Equity Shares at FVTPL*	Quoted bonds at FVTOCI	Total credit risk exposure
Financial and Insurance Activities	9,98,000	5,29,444	1,28,43,415	1,43,70,859
Sovereign	-	-	1,60,77,154	1,60,77,154
Civil engineering	-	-	10,59,836	10,59,836
Manufacture of coke and refined petroleum products	-	-	7,34,693	7,34,693
Manufacture of other non-metallic mineral products	-	-	3,51,239	3,51,239
Manufacture of basic metals	-	-	5,52,951	5,52,951
Electric power generation, transmission & distribution	-	85,374	30,53,964	31,39,338
Housing	-	-	36,76,864	36,76,864
Real estate activities on a fee or contract basis	-	-	4,88,123	4,88,123
Liquid mutual fund	-	5,46,053	-	5,46,053
Infrastructure	-	-	1,19,21,535	1,19,21,535
Wholesale of food, beverages and tobacco	-	-	13,18,933	13,18,933
Manufacture of chemicals and chemical products	-	-	1,99,490	1,99,490
Total	9,98,000	11,60,871	5,22,78,197	5,44,37,068

* Mutual funds includes AIF and ETF. Equity shares includes Invit.



24.3 Credit exposure by credit rating

The table below provides information regarding the credit risk exposure of the Company by classifying assets according to the Company's credit ratings of counterparties:

(Rs. in 000's)

As at March 31, 2025	High grade (Sovereign)	Standard grade (AA and above)	Not rated	Total
Fixed Deposits at amortised cost	-	-	13,50,000	13,50,000
Mutual funds & Equity Shares at FVTPL*	-	68,543	29,03,735	29,72,278
Quoted bonds at FVTOCI	2,39,65,056	5,44,09,398	-	7,83,74,454
Total credit risk exposure	2,39,65,056	5,44,77,941	42,53,735	8,26,96,732

(Rs. in 000's)

As at March 31, 2024	High grade (Sovereign)	Standard grade (AA and above)	Not rated	Total
Fixed Deposits at amortised cost	-	-	9,98,000	9,98,000
Mutual funds & Equity Shares at FVTPL*	-	-	11,60,871	11,60,871
Quoted bonds at FVTOCI	1,60,77,154	3,62,01,043	-	5,22,78,197
Total credit risk exposure	1,60,77,154	3,62,01,043	21,58,871	5,44,37,068

* Mutual funds includes AIF and ETF. Equity shares includes InvIT.

The Company's maximum exposure to credit risk from insurance contract assets issued is Nil (previous year Nil).

The Company actively manages its product mix to ensure that there is no significant concentration of credit risk.

25. IMPAIRMENT LOSSES ON FINANCIAL INVESTMENTS SUBJECT TO IMPAIRMENT ASSESSMENT

Debt instruments measured at FVTOCI

The table below shows the fair value of the Company's debt instruments measured at FVTOCI by credit risk, based on its internal credit rating system. Details of the Company's internal grading system are explained in Note 2.5.2.7.1:

(Rs. in 000's)

Internal rating grade	As at March 31, 2025	As at March 31, 2024
Performing	7,83,74,454	5,22,78,197
Total Net Amount	7,83,74,454	5,22,78,197

An analysis of changes in the fair value is as follows:

(Rs. in 000's)

Particulars	As at March 31, 2025	As at March 31, 2024
Fair value as at April 01	5,22,78,927	3,16,00,910
New assets originated or purchased	2,76,17,924	2,51,29,786
Assets derecognised or matured	(26,12,804)	(49,04,575)
Change in fair value	10,92,464	4,52,806
Fair value as at March 31	7,83,76,511	5,22,78,927

An analysis of changes in the ECLs is as follows:

(Rs. in 000's)

Particulars	As at March 31, 2025	As at March 31, 2024
ECL as at April 01	730	521
New assets originated or purchased	1,054	293
Assets derecognised or matured (excluding write-offs)	(137)	(89)
Change in ECL	410	5
ECL as at March 31	2,057	730



26. TOTAL INVESTMENT INCOME

The table below presents an analysis of total investment income and insurance finance result recognised in profit or loss and OCI during the year:

For the year ended March 31, 2025

(Rs. in 000's)

Investment income	Investments at FVTPL			Investments at FVTOCI	Investments at Amortized Cost	Total
	Mutual Fund*	Equity Shares*	AIF	Quoted bonds	Fixed Deposit	
Amounts recognised in the profit or loss						
Interest income on financial assets carried at fair value through other comprehensive income	-	-	-	45,17,765	-	45,17,765
Interest income on financial assets carried at amortized cost	-	-	-	-	70,307	70,307
Interest and dividend income on financial assets carried at fair value through profit and loss	-	10,824	65,816	-	-	76,640
Net gain on sale of investments	90,803	26,828	15,934	-	-	1,33,565
Net fair value gains/(losses) on financial assets at fair value through profit or loss	2,803	(31,500)	(10,740)	-	-	(39,437)
Impairment loss on financial assets	-	-	-	(1,327)	-	(1,327)
Total amounts recognised in the profit or loss	93,606	6,152	71,010	45,16,438	70,307	47,57,513
Amounts recognised in OCI	-	-	-	10,92,464	-	10,92,464
Total investment income	93,606	6,152	71,010	56,08,902	70,307	58,49,977

For the year ended March 31, 2024

(Rs. in 000's)

Investment income	Investments at FVTPL			Investments at FVTOCI	Investments at Amortized Cost	Total
	Mutual Fund*	Equity Shares*	AIF	Quoted bonds	Fixed Deposit	
Amounts recognised in the profit or loss						
Interest income on financial assets carried at fair value through other comprehensive income	-	-	-	29,01,292	-	29,01,292
Interest income on financial assets carried at amortized cost	-	-	-	-	37,896	37,896
Interest and dividend income on financial assets carried at fair value through profit and loss	-	10,629	20,337	-	-	30,966
Net gain on sale of investments	79,659	-	-	(7,586)	-	72,073
Net fair value gains/(losses) on financial assets at fair value through profit or loss	711	24,343	14,156	-	-	39,210
Impairment loss on financial assets	-	-	-	(209)	-	(209)
Total amounts recognised in the profit or loss	80,370	34,972	34,493	28,93,497	37,896	30,81,228
Amounts recognised in OCI	-	-	-	496,963	-	4,96,963
Total investment income	80,370	34,972	34,493	33,90,460	37,896	35,78,191

* Mutual Fund includes ETF and Equity Shares includes InvIT

The Company manages separate asset portfolios to support the insurance contracts issued in each major product line.

Fixed deposits are placed in the schedule bank where the loss given default is considered negligible due to high regulatory framework and having A1+ rating from rating agencies reducing their probability of default. The company has not recognised excepted credit loss on the fixed deposits.



26.1 MUTUAL FUNDS & EQUITY SHARES AT FAIR VALUE THROUGH PROFIT OR LOSS

The breakdown of financial assets measured at FVTPL is, as follows:

Particulars	(Rs. in 000's)	
	As at March 31, 2025	As at March 31, 2024
Mutual Funds*	28,33,735	9,60,824
Equity Shares**	1,38,543	2,00,047
Total	29,72,278	11,60,871

* Mutual Funds includes ETF and AIF

** Equity Shares includes InvIT

26.2 QUOTED BONDS MEASURED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

The breakdown of quoted bonds measured at FVTOCI is, as follows. For information relating to impairment refer to Note 25.

Particulars	(Rs. in 000's)	
	As at March 31, 2025	As at March 31, 2024
Government debt instruments (Indian)	2,53,16,236	1,60,77,154
Other debt instruments	5,30,58,218	3,62,01,043
Total	7,83,74,454	5,22,78,197

27. Maturity profiles

The following table summarises the maturity profile of insurance contracts issued that are liabilities based on the estimates of the future cash flows expected to be settled.

Particulars	As at March 31, 2025			As at March 31, 2024		
	No more than 12 months	More than 12 months	Total	No more than 12 months	More than 12 months	Total
Insurance contract liabilities						
Insurance contracts issued	3,98,92,060	85,60,417	4,84,52,477	2,74,44,405	69,91,080	3,44,35,485

27.1 Maturity analysis for financial liabilities (basis future cash flow)

The following table summarises the maturity profile of financial liabilities of the Company based on remaining undiscounted contractual cash flows:

As at March 31, 2025	(Rs. in 000's)						Total
	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	>5 years	
Financial liabilities							
Borrowings	-	-	-	-	-	25,00,000	25,00,000
Lease Liabilities	2,31,966	2,31,460	2,37,230	2,12,560	1,44,196	2,68,077	13,25,489
Accounts payable	41,25,042	-	-	-	-	-	41,25,042
Salaries and employee benefit liabilities*	4,20,204	-	-	-	-	-	4,20,204
Others	12,228	-	-	-	-	-	12,228
Total	47,89,440	2,31,460	2,37,230	2,12,560	1,44,196	27,68,077	83,82,963



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

(Rs. in 000's)

As at March 31, 2024	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	>5 years	Total
Financial liabilities							
Borrowings	-	-	-	-	-	25,00,000	25,00,000
Lease Liabilities	1,88,371	1,93,653	1,94,393	1,95,802	1,66,972	1,44,303	10,83,494
Accounts payable	36,64,921	-	-	-	-	-	36,64,921
Salaries and employee benefit liabilities*	4,01,840	-	-	-	-	-	4,01,840
Others	13,298	-	-	-	-	-	13,298
Total	42,68,430	1,93,653	1,94,393	1,95,802	1,66,972	26,44,303	76,63,553

*Does not include provision for defined benefit plans.

28. Interest rate risk

The Company is exposed to interest rate risk through its debt instruments held. The Company does not have the exposure to interest rate risk in respect of liabilities or assets for incurred claims as cash flows are expected to be settled within a year from when claims are incurred considering the short-term nature of the insurance contracts. The Company's exposure to interest rate risk sensitive to debt instruments is as follows:

(Rs. in 000's)


Particulars	As at March 31, 2025	As at March 31, 2024
Debt instruments at FVTOCI	7,83,74,454	5,22,78,197

The following analysis is performed for reasonably possible movements in key variables with all other variables held constant, showing the impact on profit before tax and equity. The correlation of variables will have a significant effect in determining the ultimate impact of interest rate risk, but to demonstrate the impact due to changes in variables, variables have been changed on an individual basis. It should be noted that movements in these variables are non-linear. The method used for deriving sensitivity information and significant variables has not changed from the previous year.

Below table demonstrates the impact on profit before tax and equity because of change in interest rate by +/-1% using stress testing methodology:

(Rs. in 000's)

Particulars	Change in Interest rate	For the year ended March 31, 2025		For the year ended March 31, 2024	
		Impact on profit before tax	Impact on equity	Impact on profit before tax	Impact on equity
Insurance and reinsurance contracts	+100 bps	-	-	-	-
Debt instruments	+100 bps	(30,16,213)	(22,57,092)	(20,83,298)	(15,58,974)
Insurance and reinsurance contracts	-100 bps	-	-	-	-
Debt instruments	-100 bps	32,11,284	24,03,068	22,35,552	16,72,908



29. INSURANCE RELATED DISCLOSURES

29.1 Insurance contracts issued and reinsurance contracts held

The following tables show the concentration of net insurance contract liabilities by group of contracts:

(Rs. in 000's)

Particulars	For the year ended March 31, 2025			For the year ended March 31, 2024		
Group of Contracts	Insurance Service Revenue	Reinsurance Cession	Net Retained	Insurance Service Revenue	Reinsurance Cession	Net Retained
Retail	4,19,32,884	99,96,059	3,19,36,825	3,21,13,424	77,27,226	2,43,86,198
Group	1,64,66,198	23,36,563	1,41,29,635	1,20,65,235	15,00,746	1,05,64,489
Total net insurance contracts	5,83,99,082	1,23,32,622	4,60,66,460	4,41,78,659	92,27,972	3,49,50,687

29.2 Sensitivities

The below table shows how the equity and profit before tax would have increased or decreased if changes in the future assumptions in insurance and inflation risk that were reasonably possible at the reporting date had occurred. This analysis presents the sensitivities both before and after risk mitigation by reinsurance and assumes that the other variables remain constant.

(Rs. in 000's)

For the year ended March 31, 2025	Change in assumptions	Impact on profit before tax gross of reinsurance	Impact on profit before tax net of reinsurance	Impact on equity gross of reinsurance	Impact on equity net of reinsurance
Weighted average term to settlement					
Expected loss (Insurance Risk)	10%	(37,01,520)	(29,81,520)	(27,69,921)	(22,31,131)
Inflation rate	10%	(30,09,074)	(24,55,889)	(22,51,750)	(18,37,791)

(Rs. in 000's)

For the year ended March 31, 2024	Change in assumptions	Impact on profit before tax gross of reinsurance	Impact on profit before tax net of reinsurance	Impact on equity gross of reinsurance	Impact on equity net of reinsurance
Weighted average term to settlement					
Expected loss (Insurance Risk)	10%	(26,07,000)	(20,81,000)	(19,50,870)	(15,57,254)
Inflation rate	10%	(24,08,176)	(19,61,972)	(18,02,086)	(14,68,183)

There has been no change in assumptions and methods used in preparing the sensitivities analysis from prior year.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

29.3 Claims development table

The following tables show the estimates of cumulative incurred claims, including both claims notified and IBNR for each successive accident year at each reporting date, together with cumulative payments to date.

Gross undiscounted liabilities for incurred claims as at March 31, 2025 – Retail

(Rs. in 000's)

Ultimate gross loss estimate*	Prior to Mar 2021	2021-22	2022-23	2023-24	2024-25	Total
At end of accident year**	2,41,26,442	1,10,44,008	1,37,78,339	1,93,75,352	2,57,65,861	9,40,90,002
One year later	2,41,28,605	1,09,49,804	1,38,54,434	1,92,13,026	-	6,81,45,869
Two years later	2,40,97,746	1,08,72,614	1,39,25,421	-	-	4,88,95,781
Three years later	2,41,09,450	1,08,67,494	-	-	-	3,49,76,944
Gross estimates of the undiscounted amount of the claims*	2,41,09,450	1,08,67,494	1,39,25,421	1,92,13,026	2,57,65,861	9,38,81,252
Cumulative Gross Claims Paid						
At end of accident year**	2,37,99,013	94,24,529	1,18,12,112	1,68,33,514	2,29,30,376	8,47,99,544
One year later	2,38,82,911	1,06,82,893	1,36,68,833	1,88,72,300	-	6,71,06,937
Two years later	2,39,17,623	1,07,42,880	1,37,64,764	-	-	4,84,25,267
Three years later	2,39,49,751	1,07,69,835	-	-	-	3,47,19,586
Cumulative Payments to date	2,39,49,751	1,07,69,835	1,37,64,764	1,88,72,300	2,29,30,376	9,02,87,026
Incurred Claims*	1,59,699	97,659	1,60,657	3,40,726	28,35,484	35,94,225
Total gross liabilities for incurred claims						35,94,225

* Ultimate loss liabilities and liabilities estimate is excluding risk adjustment and claim handling expense reserve.

** For accident years prior to Mar'21, ultimate loss estimate and cumulative claims paid position are at Mar'22 end in the first lag.

Claims paid is excluding Health check up, TPA, capitation cost and compensation costs.

(Rs. in 000's)

Particulars	Note	Claim Reserve	Claim Handling Expense Reserve	Risk adjustment	Total
Total gross liabilities for incurred claims					
Related to					
Retail	31.1.1	35,94,225	93,146	2,79,938	39,67,309
Insurance payables					15,53,049
Total					55,20,358



Gross undiscounted liabilities for incurred claims as at March 31, 2025 – Group

(Rs. in 000's)

Ultimate gross loss estimate*	Prior to Mar 2021	2021-22	2022-23	2023-24	2024-25	Total
At end of accident year**	38,74,372	19,72,897	30,21,442	65,81,578	84,67,404	2,39,17,693
One year later	39,30,406	17,37,427	27,56,932	65,15,788	-	1,49,40,553
Two years later	39,68,641	18,05,432	28,10,404	-	-	85,84,477
Three years later	39,79,129	18,34,999	-	-	-	58,14,128
Gross estimates of the undiscounted amount of the claims*	39,79,129	18,34,999	28,10,404	65,15,788	84,67,404	2,36,07,724
Cumulative Gross Claims Paid						
At end of accident year**	38,00,802	14,75,783	20,89,530	54,27,655	67,57,182	1,95,50,952
One year later	38,34,165	16,95,163	27,01,906	63,29,034	-	1,45,60,268
Two years later	38,62,572	17,13,486	27,51,931	-	-	83,27,989
Three years later	38,73,285	17,46,222	-	-	-	56,19,507
Cumulative Payments to date	38,73,285	17,46,222	27,51,931	63,29,034	67,57,182	2,14,57,654
Incurred Claims*	1,05,843	88,777	58,473	1,86,754	17,10,221	21,50,068
Total gross liabilities for incurred claims						21,50,068

* Ultimate loss liabilities and liabilities estimate is excluding risk adjustment and claim handling expense reserve.

** For accident years prior to Mar'21, ultimate loss estimate and cumulative claims paid position are at Mar'22 end in the first lag.

Claims paid is excluding Health check up, TPA, capitation cost and compensation costs.

(Rs. in 000's)

Particulars	Note	Claim Reserve	Claim Handling Expense Reserve	Risk adjustment	Total
Total gross liabilities for incurred claims					
Related to					
Group	31.1.2	21,50,069	51,071	3,12,268	25,13,408
Insurance payables					3,29,695
Total					28,43,103

30. INSURANCE SERVICE EXPENSE

The breakdown of insurance service expenses by major product lines is presented below:

For the year ended March 31, 2025

(Rs. in 000's)

Particulars	Retail	Group	Total
Incurred claims and other expenses	2,76,86,391	92,29,982	3,69,16,373
Amortisation of insurance acquisition cash flows	1,25,52,372	53,98,389	1,79,50,761
Losses on onerous contracts and reversals of those contracts	-	3,47,610	3,47,610
Total	4,02,38,763	1,49,75,981	5,52,14,744

For the year ended March 31, 2024

(Rs. in 000's)

Particulars	Retail	Group	Total
Incurred claims and other expenses	2,08,91,025	68,93,817	2,77,84,842
Amortisation of insurance acquisition cash flows	90,87,100	39,24,980	1,30,12,080
Total	2,99,78,125	1,08,18,797	4,07,96,922



31. INSURANCE AND REINSURANCE CONTRACTS

The breakdown of groups of insurance and reinsurance contracts held, that are in an asset position and those in a liability position is set out in the table below:

(Rs. in 000's)

Particulars	As at March 31, 2025			As at March 31, 2024		
	Assets	Liabilities	Net	Assets	Liabilities	Net
Insurance contracts issued						
Retail	1,04,33,318	(4,26,50,275)	(3,22,16,957)	89,80,652	(3,33,68,803)	(2,43,88,151)
Group	75,16,756	(2,37,52,276)	(1,62,35,520)	49,47,768	(1,49,95,102)	(1,00,47,334)
Total insurance contracts issued	1,79,50,074	(6,64,02,551)	(4,84,52,477)	1,39,28,420	(4,83,63,905)	(3,44,35,485)
Reinsurance contracts held						
Obligatory	18,01,075	(6,47,437)	11,53,638	15,48,773	(1,39,764)	14,09,009
Voluntary Quota Share	42,31,355	(27,12,815)	15,18,540	52,78,484	(19,61,441)	33,17,043
Surplus Personal Accident	62,357	1,18,377	1,80,734	2,30,255	(40,062)	1,90,193
Surplus Critical Illness	3,49,241	7,62,696	11,11,937	8,23,295	-	8,23,295
Travel Voluntary Quota Share	1,985	(7,587)	(5,602)	44,401	(9,225)	35,176
Total Reinsurance contracts held	64,46,013	(24,86,766)	39,59,247	79,25,208	(21,50,492)	57,74,716



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

31.1 Roll-forward of net asset or liability for insurance contracts issued showing the liability for remaining coverage and the liability for incurred claims

The Company disaggregates information to provide disclosure in respect of major product lines separately: Retail and Group. This disaggregation has been determined based on how the Company is managed.

31.1.1 Retail

The roll-forward of the net asset or liability for insurance contracts issued, showing the liability for remaining coverage and the liability for incurred claims for Retail business, is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Liabilities for remaining coverage		Liabilities for incurred claim		Assets for insurance acquisition cash flows	Total
	Excluding loss component*	Loss Component	Estimates of the present value of future cash flows	Risk adjustment		
Insurance contract liabilities as at April 01, 2024	(2,90,41,675)	-	(40,30,191)	(2,96,937)	-	(3,33,68,803)
Insurance contract assets as at April 01, 2024	-	-	-	-	89,80,652	89,80,652
Net insurance contract assets/(liabilities) as at April 01, 2024	(2,90,41,675)	-	(40,30,191)	(2,96,937)	89,80,652	(2,43,88,151)
Insurance revenue	4,19,32,884	-	-	-	-	4,19,32,884
Insurance service expenses	-	-	-	-	-	-
Incurred claims and other expenses	-	-	(2,77,03,390)	16,999	-	(2,76,86,391)
Amortisation of insurance acquisition cash flows	-	-	-	-	(1,25,52,372)	(1,25,52,372)
Losses on onerous contracts and reversals of those contracts	-	-	-	-	-	-
Cash flows	-	-	-	-	-	-
Premiums received	(5,00,21,126)	-	-	-	-	(5,00,21,126)
Claims and other expenses paid	-	-	2,64,93,161	-	-	2,64,93,161
Insurance acquisition cash flows	-	-	-	-	1,40,05,038	1,40,05,038
Total cash flows	(5,00,21,126)	-	2,64,93,161	-	1,40,05,038	(95,22,927)
Net insurance contract assets/(liabilities) as at March 31, 2025	-	-	-	-	-	-
Insurance contract liabilities as at March 31, 2025	(3,71,29,917)	-	(52,40,420)	(2,79,938)	-	(4,26,50,275)
Insurance contract assets as at March 31, 2025	-	-	-	-	1,04,33,318	1,04,33,318
Net insurance contract assets/(liabilities) as at March 31, 2025	(3,71,29,917)	-	(52,40,420)	(2,79,938)	1,04,33,318	(3,22,16,957)



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Liabilities for remaining coverage	Liabilities for incurred claim		Assets for insurance acquisition cash flows	Total
	Excluding loss component*	Estimates of the present value of future cash flows	Risk adjustment		
Insurance contract liabilities as at April 01, 2023	(2,18,04,701)	(32,34,215)	(3,76,827)	-	(2,54,15,743)
Insurance contract assets as at April 01, 2023	-	-	-	62,84,427	62,84,427
Net insurance contract assets/(liabilities) as at April 01, 2023	(2,18,04,701)	(32,34,215)	(3,76,827)	62,84,427	(1,91,31,316)
Insurance revenue	3,22,31,976	-	-	-	3,22,31,976
Insurance service expenses					
Incurred claims and other expenses	-	(2,09,70,915)	79,890	-	(2,08,91,025)
Amortisation of insurance acquisition cash flows	-	-	-	(90,87,100)	(90,87,100)
Cash flows					
Premiums received	(3,94,68,950)	-	-	-	(3,94,68,950)
Claims and other expenses paid	-	2,01,74,939	-	-	2,01,74,939
Insurance acquisition cash flows	-	-	-	1,17,83,325	1,17,83,325
Total cash flows	(3,94,68,950)	2,01,74,939	-	1,17,83,325	(75,10,686)
Net insurance contract assets/(liabilities) as at March 31, 2024					
Insurance contract liabilities as at March 31, 2024	(2,90,41,675)	(40,30,191)	(2,96,937)	-	(3,33,68,803)
Insurance contract assets as at March 31, 2024	-	-	-	89,80,652	89,80,652
Net insurance contract assets/(liabilities) as at March 31, 2024	(2,90,41,675)	(40,30,191)	(2,96,937)	89,80,652	(2,43,88,151)

Notes:

- Insurance acquisition cash flows were allocated on a straight-line basis during the coverage year of the respective group of contracts. Please see extracts from accounting policy for details on Note 2.3.2.10.
- The Company has made an accounting policy choice for the product line to recognise net insurance finance expense in profit or loss only. Please refer to Note 2.3.2.16 for details.
- Any refunds of premiums have been included in this line*.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

The expected timing of when assets for insurance acquisition cash flows will be derecognised and included in the measurement of the group of insurance contracts to which they are allocated is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	Total
Expected timing of derecognition of assets balance as at March 31, 2025	80,39,224	17,69,833	6,24,259	-	-	1,04,33,316

As at March 31, 2024						(Rs. in 000's)
Particulars	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	Total
Expected timing of derecognition of assets balance as at March 31, 2024	67,95,412	16,43,887	5,41,353	-	-	89,80,652



1

NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

31.1.2 Group

The roll-forward of the net asset or liability for insurance contracts issued, showing the liability for remaining coverage and the liability for incurred claims for Group business, is disclosed in the table below:

As at March 31, 2025

(Rs. in 000's)

Particulars	Liabilities for remaining coverage		Liabilities for incurred claim		Assets for insurance acquisition cash flows	Total
	Excluding loss component*	Loss Component	Estimates of the present value of future cash flows	Risk adjustment		
Insurance contract liabilities as at April 01, 2024	(1,30,40,829)	-	(16,49,000)	(3,05,273)	-	(1,49,95,102)
Insurance contract assets as at April 01, 2024	-	-	-	-	49,47,768	49,47,768
Net insurance contract assets/(liabilities) as at April 01, 2024	(1,30,40,829)	-	(16,49,000)	(3,05,273)	49,47,768	(1,00,47,334)
Insurance revenue	1,64,66,198	-	-	-	-	1,64,66,198
Insurance service expenses						
Incurred claims and other expenses	-	98,827	(93,21,814)	(6,995)	-	(92,29,982)
Amortisation of insurance acquisition cash flows	-	-	-	-	(53,98,389)	(53,98,389)
Losses on onerous contracts and reversals of those contracts	-	(3,47,610)	-	-	-	(3,47,610)
Cash flows						
Premiums received	(2,40,85,759)	-	-	-	-	(2,40,85,759)
Claims and other expenses paid	-	-	84,39,979	-	-	84,39,979
Insurance acquisition cash flows	-	-	-	-	79,67,377	79,67,377
Total cash flows	(2,40,85,759)	-	84,39,979	-	79,67,377	(76,78,403)
Net insurance contract assets/(liabilities) as at March 31, 2025						
Insurance contract liabilities as at March 31, 2025	(2,06,60,390)	(2,48,783)	(25,30,835)	(3,12,268)	-	(2,37,52,276)
Insurance contract assets as at March 31, 2025	-	-	-	-	75,16,756	75,16,756
Net insurance contract assets/(liabilities) as at March 31, 2025	(2,06,60,390)	(2,48,783)	(25,30,835)	(3,12,268)	75,16,756	(1,62,35,520)



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Liabilities for remaining coverage	Liabilities for incurred claim		Assets for insurance acquisition cash flows	Total
	Excluding loss component*	Estimates of the present value of future cash flows	Risk adjustment		
Insurance contract liabilities as at April 01, 2023	(83,98,083)	(12,29,524)	(3,36,658)	-	(99,64,265)
Insurance contract assets as at April 01, 2023	-	-	-	34,44,220	34,44,220
Net insurance contract assets/(liabilities) as at April 01, 2023	(83,98,083)	(12,29,524)	(3,36,658)	34,44,220	(65,20,045)
Insurance revenue	1,19,46,683	-	-	-	1,19,46,683
Insurance service expenses					
Incurred claims and other expenses	-	(69,25,202)	31,385	-	(68,93,817)
Amortisation of insurance acquisition cash flows	-	-	-	(39,24,980)	(39,24,980)
Cash flows					
Premiums received	(1,65,89,429)	-	-	-	(1,65,89,429)
Claims and other expenses paid	-	65,05,726	-	-	65,05,726
Insurance acquisition cash flows	-	-	-	54,28,528	54,28,528
Total cash flows	(1,65,89,429)	65,05,726	-	54,28,528	(46,55,175)
Net insurance contract assets/(liabilities) as at March 31, 2024					
Insurance contract liabilities as at March 31, 2024	(1,30,40,829)	(16,49,000)	(3,05,273)	-	(1,49,95,102)
Insurance contract assets as at March 31, 2024	-	-	-	49,47,768	49,47,768
Net insurance contract assets/(liabilities) as at March 31, 2024	(1,30,40,829)	(16,49,000)	(3,05,273)	49,47,768	(1,00,47,334)

Notes:

- Insurance acquisition cash flows were allocated on a straight-line basis during the coverage year of the respective group of contracts. Please see extracts from accounting policy for details on Note 2.3.2.10.
- The Company has made an accounting policy choice for the product line to recognise net insurance finance expense in profit or loss only. Please refer to Note 2.3.2.16 for details.
- Any refunds of premiums have been included in this line*.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

The expected timing of when assets for insurance acquisition cash flows will be derecognised and included in the measurement of the group of insurance contracts to which they are allocated is disclosed in the table below:

As at March 31, 2025 **(Rs. in 000's)**

Particulars	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	Total
Expected timing of derecognition of assets balance as at March 31, 2025	38,50,640	17,15,629	10,74,438	6,27,887	2,48,164	75,16,758

As at March 31, 2024 **(Rs. in 000's)**

Particulars	Up to 1 year	1-2 years	2-3 years	3-4 years	4-5 years	Total
Expected timing of derecognition of assets balance as at March 31, 2024	26,51,642	11,47,603	5,80,493	3,98,311	1,69,719	49,47,768



31.2 Roll-forward of net asset or liability for reinsurance contracts held showing the assets for remaining coverage and the amounts recoverable on incurred claims

31.2.1 Obligatory

The roll-forward of the net asset or liability for reinsurance contracts held showing assets for remaining coverage and amounts recoverable on incurred claims arising on Obligatory reinsurance treaty is disclosed in the table below:

(Rs. in 000's)

Particulars	Assets for remaining coverage		Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2024	9,94,775	-	5,34,169	19,829	-	15,48,773
Reinsurance contract liabilities as at April 01, 2024	-	-	-	-	(1,39,764)	(1,39,764)
Net reinsurance contract assets/(liabilities) as at April 01, 2024	9,94,775	-	5,34,169	19,829	(1,39,764)	14,09,009
An allocation of reinsurance premiums	(23,45,956)	-	-	-	-	(23,45,956)
Amount recoverable from Reinsurers :						
Recoveries of Commission	-	-	-	-	3,77,364	3,77,364
Recoveries of incurred claims and other expenses	-	(3,953)	14,95,054	1,488	-	14,92,589
Net income or expense from reinsurance contracts held	(23,45,956)	(3,953)	14,95,054	1,488	3,77,364	(4,76,003)
Recoveries and reversals of recoveries of losses on onerous contracts	-	13,904	-	-	-	13,904
Premiums paid	7,03,744	-	-	-	-	7,03,744
Amounts received :						
Claims received	-	-	(3,42,165)	-	-	(3,42,165)
Commission received	-	-	-	-	(1,54,851)	(1,54,851)
Total cash flows	7,03,744	-	(3,42,165)	-	(1,54,851)	2,06,728
Net Reinsurance contract assets/(liabilities) as at March 31, 2025						
Reinsurance contract assets as at March 31, 2025	-	9,951	16,87,058	21,317	82,749	18,01,075
Reinsurance contract liabilities as at March 31, 2025	(6,47,437)	-	-	-	-	(6,47,437)
Net Reinsurance contract assets/(liabilities) as at March 31, 2025	(6,47,437)	9,951	16,87,058	21,317	82,749	11,53,638



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Assets for remaining coverage	Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2023	7,19,636	3,89,165	26,756	-	11,35,557
Reinsurance contract liabilities as at April 01, 2023	-	-	-	(1,01,625)	(1,01,625)
Net reinsurance contract assets/(liabilities) as at April 01, 2023	7,19,636	3,89,165	26,756	(1,01,625)	10,33,932
An allocation of reinsurance premiums	(17,97,629)	-	-	-	(17,97,629)
Amount recoverable from Reinsurers :					
Recoveries of Commission	-	-	-	3,02,674	3,02,674
Recoveries of incurred claims and other expenses	-	11,26,720	(6,927)	-	11,19,793
Net income or expense from reinsurance contracts held	(17,97,629)	11,26,720	(6,927)	3,02,674	(3,75,162)
Premiums paid	20,72,768	-	-	-	20,72,768
Amounts received :					
Claims received	-	(9,81,716)	-	-	(9,81,716)
Commission received	-	-	-	(3,40,813)	(3,40,813)
Total cash flows	20,72,768	(9,81,716)	-	(3,40,813)	7,50,239
Net Reinsurance contract assets/(liabilities) as at March 31, 2024					
Reinsurance contract assets as at March 31, 2024	9,94,775	5,34,169	19,829	-	15,48,773
Reinsurance contract liabilities as at March 31, 2024	-	-	-	(1,39,764)	(1,39,764)
Net Reinsurance contract assets/(liabilities) as at March 31, 2024	9,94,775	5,34,169	19,829	(1,39,764)	14,09,009



31.2.2 Voluntary Quota Share

The roll-forward of the net asset or liability for reinsurance contracts held showing assets for remaining coverage and amounts recoverable on incurred claims arising on Voluntary quota share treaty is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Assets for remaining coverage		Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2024	34,95,512	-	17,43,398	39,574	-	52,78,484
Reinsurance contract liabilities as at April 01, 2024	-	-	-	-	(19,61,441)	(19,61,441)
Net reinsurance contract assets/(liabilities) as at April 01, 2024	34,95,512	-	17,43,398	39,574	(19,61,441)	33,17,043
An allocation of reinsurance premiums	(94,45,566)	-	-	-	-	(94,45,566)
Amount recoverable from Reinsurers :						
Recoveries of Commission	-	-	-	-	40,73,907	40,73,907
Recoveries of incurred claims and other expenses	-	-	53,46,699	13,694	-	53,60,393
Net income or expense from reinsurance contracts held	(94,45,566)	-	53,46,699	13,694	40,73,907	(11,266)
Recoveries and reversals of recoveries of losses on onerous contracts	-	-	-	-	-	-
Premiums paid	32,37,239	-	-	-	-	32,37,239
Amounts received :					-	
Claims received	-	-	(39,38,264)	-	-	(39,38,264)
Commission received	-	-	-	-	(10,86,212)	(10,86,212)
Total cash flows	32,37,239	-	(39,38,264)	-	(10,86,212)	(17,87,237)
Net Reinsurance contract assets/(liabilities) as at March 31, 2025						
Reinsurance contract assets as at March 31, 2025	-	-	31,51,833	53,268	10,26,254	42,31,355
Reinsurance contract liabilities as at March 31, 2025	(27,12,815)	-	-	-	-	(27,12,815)
Net Reinsurance contract assets/(liabilities) as at March 31, 2025	(27,12,815)	-	31,51,833	53,268	10,26,254	15,18,540



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Assets for remaining coverage	Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2023	27,33,076	12,53,133	52,289	-	40,38,498
Reinsurance contract liabilities as at April 01, 2023	-	-	-	(16,09,903)	(16,09,903)
Net reinsurance contract assets/(liabilities) as at April 01, 2023	27,33,076	12,53,133	52,289	(16,09,903)	24,28,595
An allocation of reinsurance premiums	(70,52,890)	-	-	-	(70,52,890)
Amount recoverable from Reinsurers :					
Recoveries of Commission	-	-	-	30,42,794	30,42,794
Recoveries of incurred claims and other expenses	-	39,28,432	(12,715)	-	39,15,717
Net income or expense from reinsurance contracts held	(70,52,890)	39,28,432	(12,715)	30,42,794	(94,379)
Premiums paid	78,15,326	-	-	-	78,15,326
Amounts received :					
Claims received	-	(34,38,167)	-	-	(34,38,167)
Commission received	-	-	-	(33,94,332)	(33,94,332)
Total cash flows	78,15,326	(34,38,167)	-	(33,94,332)	9,82,827
Net Reinsurance contract assets/(liabilities) as at March 31, 2024					
Reinsurance contract assets as at March 31, 2024	34,95,512	17,43,398	39,574	-	52,78,484
Reinsurance contract liabilities as at March 31, 2024	-	-	-	(19,61,441)	(19,61,441)
Net Reinsurance contract assets/(liabilities) as at March 31, 2024	34,95,512	17,43,398	39,574	(19,61,441)	33,17,043



31.2.3 Surplus Personal Accident

The roll-forward of the net asset or liability for reinsurance contracts held showing assets for remaining coverage and amounts recoverable on incurred claims arising on Surplus personal accident treaty is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Assets for remaining coverage		Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2024	1,10,470	-	1,13,059	6,726	-	2,30,255
Reinsurance contract liabilities as at April 01, 2024	-	-	-	-	(40,062)	(40,062)
Net reinsurance contract assets/(liabilities) as at April 01, 2024	1,10,470	-	1,13,059	6,726	(40,062)	1,90,193
An allocation of reinsurance premiums	(1,37,882)	-	-	-	-	(1,37,882)
Amount recoverable from Reinsurers :						
Recoveries of Commission	-	-	-	-	53,622	53,622
Recoveries of incurred claims and other expenses	-	-	53,768	354	-	54,122
Net income or expense from reinsurance contracts held	(1,37,882)	-	53,768	354	53,622	(30,138)
Recoveries and reversals of recoveries of losses on onerous contracts	-	-	-	-	-	-
Premiums paid	1,45,789	-	-	-	-	1,45,789
Amounts received :						
Claims received	-	-	(61,818)	-	-	(61,818)
Commission received	-	-	-	-	(63,292)	(63,292)
Total cash flows	1,45,789	-	(61,818)	-	(63,292)	20,679
Net Reinsurance contract assets/(liabilities) as at March 31, 2025						
Reinsurance contract assets as at March 31, 2025	-	-	1,05,009	7,080	(49,732)	62,357
Reinsurance contract liabilities as at March 31, 2025	1,18,377	-	-	-	-	1,18,377
Net Reinsurance contract assets/(liabilities) as at March 31, 2025	1,18,377	-	1,05,009	7,080	(49,732)	1,80,734



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Assets for remaining coverage	Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2023	16,827	67,391	9,418	-	93,636
Reinsurance contract liabilities as at April 01, 2023	-	-	-	(15,316)	(15,316)
Net reinsurance contract assets/(liabilities) as at April 01, 2023	16,827	67,391	9,418	(15,316)	78,320
An allocation of reinsurance premiums	(1,78,851)	-	-	-	(1,78,851)
Amount recoverable from Reinsurers :					
Recoveries of Commission	-	-	-	53,056	53,056
Recoveries of incurred claims and other expenses	-	63,016	(2,692)	-	60,324
Net income or expense from reinsurance contracts held	(1,78,851)	63,016	(2,692)	53,056	(65,471)
Premiums paid	2,72,494	-	-	-	2,72,494
Amounts received :					
Claims received	-	(17,348)	-	-	(17,348)
Commission received	-	-	-	(77,802)	(77,802)
Total cash flows	2,72,494	(17,348)	-	(77,802)	1,77,344
Net Reinsurance contract assets/(liabilities) as at March 31, 2024					
Reinsurance contract assets as at March 31, 2024	1,10,470	1,13,059	6,726	-	2,30,255
Reinsurance contract liabilities as at March 31, 2024	-	-	-	(40,062)	(40,062)
Net Reinsurance contract assets/(liabilities) as at March 31, 2024	1,10,470	1,13,059	6,726	(40,062)	1,90,193



31.2.4 Surplus Critical Illness

The roll-forward of the net asset or liability for reinsurance contracts held showing assets for remaining coverage and amounts recoverable on incurred claims arising on Surplus critical illness treaty is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Assets for remaining coverage		Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2024	6,05,345	-	1,99,163	18,787	-	8,23,295
Reinsurance contract liabilities as at April 01, 2024	-	-	-	-	-	-
Net reinsurance contract assets/(liabilities) as at April 01, 2024	6,05,345	-	1,99,163	18,787	-	8,23,295
An allocation of reinsurance premiums	(2,90,911)	-	-	-	-	(2,90,911)
Amount recoverable from Reinsurers :						
Recoveries of Commission	-	-	-	-	4,757	4,757
Recoveries of incurred claims and other expenses	-	-	2,17,939	4,322	-	2,22,261
Net income or expense from reinsurance contracts held	(2,90,911)	-	2,17,939	4,322	4,757	(63,893)
Recoveries and reversals of recoveries of losses on onerous contracts	-	-	-	-	-	-
Premiums paid	4,48,262	-	-	-	-	4,48,262
Amounts received :						
Claims received	-	-	(90,970)	-	-	(90,970)
Commission received	-	-	-	-	(4,757)	(4,757)
Total cash flows	4,48,262	-	(90,970)	-	(4,757)	3,52,535
Net Reinsurance contract assets/(liabilities) as at March 31, 2025						
Reinsurance contract assets as at March 31, 2025	-	-	3,26,132	23,109	-	3,49,241
Reinsurance contract liabilities as at March 31, 2025	7,62,696	-	-	-	-	7,62,696
Net Reinsurance contract assets/(liabilities) as at March 31, 2025	7,62,696	-	3,26,132	23,109	-	11,11,937



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Assets for remaining coverage	Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2023	4,08,563	65,556	9,648	-	4,83,767
Reinsurance contract liabilities as at April 01, 2023	-	-	-	-	-
Net reinsurance contract assets/(liabilities) as at April 01, 2023	4,08,563	65,556	9,648	-	4,83,767
An allocation of reinsurance premiums	(1,41,679)	-	-	-	(1,41,679)
Amount recoverable from Reinsurers :					
Recoveries of Commission	-	-	-	-	-
Recoveries of incurred claims and other expenses	-	1,59,561	9,139	-	1,68,700
Net income or expense from reinsurance contracts held	(1,41,679)	1,59,561	9,139	-	27,021
Premiums paid	3,38,461	-	-	-	3,38,461
Amounts received :					
Claims received	-	(25,954)	-	-	(25,954)
Commission received	-	-	-	-	-
Total cash flows	3,38,461	(25,954)	-	-	3,12,507
Net Reinsurance contract assets/(liabilities) as at March 31, 2024					
Reinsurance contract assets as at March 31, 2024	6,05,345	1,99,163	18,787	-	8,23,295
Reinsurance contract liabilities as at March 31, 2024	-	-	-	-	-
Net Reinsurance contract assets/(liabilities) as at March 31, 2024	6,05,345	1,99,163	18,787	-	8,23,295



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

31.2.5 Travel Voluntary Quota Share

The roll-forward of the net asset or liability for reinsurance contracts held showing assets for remaining coverage and amounts recoverable on incurred claims arising on travel voluntary quota share treaty is disclosed in the table below:

As at March 31, 2025						(Rs. in 000's)
Particulars	Assets for remaining coverage		Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2024	(5,359)	-	46,514	3,246	-	44,401
Reinsurance contract liabilities as at April 01, 2024	-	-	-	-	(9,225)	(9,225)
Net reinsurance contract assets/(liabilities) as at April 01, 2023	(5,359)	-	46,514	3,246	(9,225)	35,176
An allocation of reinsurance premiums	(1,12,307)	-	-	-	-	(1,12,307)
Amount recoverable from Reinsurers :						
Recoveries of Commission	-	-	-	-	(1,620)	(1,620)
Recoveries of incurred claims and other expenses	-	-	66,476	202	-	66,678
Net income or expense from reinsurance contracts held	(1,12,307)	-	66,476	202	(1,620)	(47,249)
Recoveries and reversals of recoveries of losses on onerous contracts	-	-	-	-	-	-
Premiums paid	1,10,079	-	-	-	-	1,10,079
Amounts received :						
Claims received	-	-	(54,072)	-	-	(54,072)
Commission received	-	-	-	-	(49,536)	(49,536)
Total cash flows	1,10,079	-	(54,072)	-	(49,536)	6,471
Net Reinsurance contract assets/(liabilities) as at March 31, 2025						
Reinsurance contract assets as at March 31, 2025	-	-	58,918	3,448	(60,381)	1,985
Reinsurance contract liabilities as at March 31, 2025	(7,587)	-	-	-	-	(7,587)
Net Reinsurance contract assets/(liabilities) as at March 31, 2025	(7,587)	-	58,918	3,448	(60,381)	(5,602)



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements

As at March 31, 2024

(Rs. in 000's)

Particulars	Assets for remaining coverage	Assets for incurred claim		RI Commission	Total
	Excluding loss - recovery component	Estimates of the present value of future cash flows	Risk adjustment		
Reinsurance contract assets as at April 01, 2023	(8,022)	9,470	1,394	-	2,842
Reinsurance contract liabilities as at April 01, 2023	-	-	-	(1,206)	(1,206)
Net reinsurance contract assets/(liabilities) as at April 01, 2023	(8,022)	9,470	1,394	(1,206)	1,636
An allocation of reinsurance premiums	(56,923)	-	-	-	(56,923)
Amount recoverable from Reinsurers :					
Recoveries of Commission	-	-	-	35,586	35,586
Recoveries of incurred claims and other expenses	-	44,189	1,852	-	46,041
Net income or expense from reinsurance contracts held	(56,923)	44,189	1,852	35,586	24,704
Premiums paid	59,586	-	-	-	59,586
Amounts received :					
Claims received	-	(7,145)	-	-	(7,145)
Commission received	-	-	-	(43,605)	(43,605)
Total cash flows	59,586	(7,145)	-	(43,605)	8,836
Net Reinsurance contract assets/(liabilities) as at March 31, 2024					
Reinsurance contract assets as at March 31, 2024	(5,359)	46,514	3,246	-	44,401
Reinsurance contract liabilities as at March 31, 2024	-	-	-	(9,225)	(9,225)
Net Reinsurance contract assets/(liabilities) as at March 31, 2024	(5,359)	46,514	3,246	(9,225)	35,176



32. Borrowings

Terms of Issue are as follows:

ISIN	INE995S08010
Type, Nature and Security of the Instrument	Unsecured, subordinated, listed, rated, redeemable, taxable, non-cumulative, non-convertible debentures
Face value per security	Rs. 10,00,000
Issue size (Rs. in 000's)	Rs. 15,00,000
Issue date / Allotment date	November 15, 2021
Coupon rate	10.70%
Coupon payment frequency	Annual
Redemption date	November 15, 2031
Listing	Debt market segment on NSE
Credit Rating	"CARE AA / Stable" (As at March 31, 2024 "CARE A+/Stable")

ISIN	INE995S08028
Type, Nature and Security of the Instrument	Unsecured, subordinated, listed, rated, redeemable, taxable, non-cumulative, non-convertible debentures
Face value per security	Rs. 10,00,000
Issue size (Rs. in 000's)	Rs. 10,00,000
Issue date / Allotment date	March 15, 2022
Coupon rate	10.70%
Coupon payment frequency	Annual
Redemption date	March 15, 2032
Listing	Debt market segment on NSE
Credit Rating	"CARE AA / Stable" (As at March 31, 2024 "CARE A+/Stable")

Maturity Pattern of Borrowings

(Rs. in 000's)

Maturity Bucket	Amount
1-5 years	-
Above 5 years	25,00,000

33. Expenses of Management

During the year ended March 31, 2025, the Company has received the forbearance approval for exceeding the Expenses of Management (EOM) over the allowable limit for FY 2022-23 and FY 2023-24. The Company has also submitted the quarterly EOM plan with Insurance Regulatory and Development Authority of India ("IRDAI") on March 26, 2025 to bring the EOM within the prescribed limits by FY 2025-26 and also submitted EOM forbearance application to GI Council on April 25, 2025. Further, on the basis of discussions with IRDAI, the Company has computed expenses of management ("EOM") in accordance with accounting methodology applied before Master Circular on Actuarial, Finance and Investment Functions of Insurers dated May 17, 2024 read with clarification dated October 18, 2024 issued by IRDAI for multi-year policies and related commissions income and expenses was made applicable. The grant of such forbearance is at IRDAI's discretion and the impact of the same on the financial statements will depend on the future developments. The Company is in discussion with IRDAI and in accordance with Expense of Management Regulations 2024, a sum of 14,14,255 thousands, which is in the excess of expenses of management over the allowable limit. The Company's EOM ratio for the year ended March 31, 2025 is 37.41%.

34. Regrouping Statement

The figures for the previous year have been regrouped/ reclassified wherever necessary, to make them comparable.



NIVA BUPA HEALTH INSURANCE COMPANY LIMITED
Notes to the Financial Statements


35. Events after the balance sheet date

There have been no material subsequent events between the balance sheet date and the date of signing this report.

As per our report of even date attached

For and on behalf of the Board of Directors of
Niva Bupa Health Insurance Company Limited

For S.R. Batliboi & Co. LLP
Chartered Accountants
ICAI Firm Registration Number: 301003E/E300005



Shrawan Jalan
Partner
Membership No: 102102


Place: Mumbai
Date: May 07, 2025



Sridhar Srinivasan
Director
DIN: 07240718



Rajat Sharma
Company Secretary
Membership No: FCS7069



Krishnan Ramachandran
CEO & Managing Director
DIN: 08719264



Vishwanath Mahendra
Chief Financial Officer



Place: New Delhi
Date: May 07, 2025

CIN - L66000DL2008PLC182918

